

WEILL CORNELL MEDICINE

Signature:



Version date: May 26, 2022

A. GENERAL INFORMATION

Name: First, Middle, Last	Jim C. Hu, M.D., M.P.H.
Office address:	LeFrak Center for Robotic Surgery Department of Urology Weill Cornell Medical College 525 East 68 th Street, Starr 946 New York, NY 10065
Office telephone:	646-962-9600
Office fax:	646-962-0715
Work Email:	jch9011@med.cornell.edu
Citizenship:	United States of America

B. PERSONAL STATEMENT

My passion to lead in the field of urology stems from my commitment to mentoring trainees and faculty to advance scientific discovery and help patients. My H-index is 65 and I currently have the highest amount of *active funding* as a urologist as contact PI on two \$3 million PCORI awards, two NCI R0-1 grants and a Prostate Cancer Foundation Challenge Award, respectively. I am also mPI on an NCI R0-1 to improve nerve-sparing technique through computer vision. I demonstrated in *NEJM* significant contamination in the Prostate, Lung, Colorectal and Ovarian screening trial and was the first to demonstrate an increase in prostate cancer metastases at diagnosis following decreased national PSA screening utilization. These findings contributed to changes in national prostate cancer screening guidelines. I have also contributed the *most* publications/videos internationally to demonstrate improvements in surgical technique and outcomes. For innovation, I was awarded the Brigham and Women's Clinical Innovation Award, given annually to one faculty member for delivery of ground-breaking, high-quality care. I am most proud of my mentees, who include the Chair at Georgetown Urology, the Chief of UTMB Urology, as well as faculty at UCLA, UNC, Emory, Cedars Sinai, Lahey Clinic, Columbia, Weill Cornell, Case Western.

Professionally, I have been successful creating collaborative and research and clinical teams. I lead and collaborate on multi-center studies with Chairs of Urology at Northwestern, Johns Hopkins, Georgetown and faculty at Memorial Sloan Kettering, including Andrew Vickers the foremost biostatistician in urology. I created minimally invasive programs at Brigham and Women's and UCLA and became the busiest surgeon at each institution. I also launched satellite robotic programs at network hospitals within each of these systems and conducted outreach to support clinical growth. I served nationally on the American Urological Association Laparoscopic, Robotic Surgery and New Technologies, the Professional Guidelines, and Urology Video Education Committees, respectively and the American Board

of Urology Examination Committee. I also served on the UCLA Board of the Faculty Practice Group to learn about practice acquisition, network expansion and the shift to a funds flow model. More recently, I oversee all patient complaints and counsel physicians to improve outcomes in the Weill Cornell Department of Urology as Chair of Quality and Patient Safety. As Vice Chair of Clinical Research, I successfully mentored our residents to be awarded two of the Urology Care Foundation Resident Research Grants. Recently, I was appointed by the Dean to the 15-member Weill Cornell Committee for Review for Faculty Appointment, Promotion and Tenure.

EDUCATIONAL BACKGROUND

1. Academic Degrees:

Degree	Institution Name and Location	Dates attended	Year Awarded
B.A. Economics	Johns Hopkins University School of Arts and Sciences Baltimore, MD	9/89 – 5/93	1993
M.P.H. Health Policy and Management	Johns Hopkins School of Hygiene and Public Health Baltimore, MD	7/93 – 6/94	1998
M.D.	Baylor College of Medicine Houston, TX	7/94 – 5/98	1998

2. Post-doctoral training:

Title	Institution name and location	Dates held
General Surgery Intern and Resident	David Geffen School of Medicine at UCLA, Los Angeles, CA	7/98 – 12/99
Urology Resident	David Geffen School of Medicine at UCLA, Los Angeles, CA	1/00 – 6/04
Urologic Oncology Fellow	City of Hope National Medical Center, Duarte, CA	7/05 – 5/05

C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

State	Number	Date of issue	Date of last registration
California	A72391	7/1/2000	7/31/2016
Massachusetts	225939	7/6/2005	7/31/2012
New York	277891-1	11/30/2014	6/30/2018

DEA number:	BH7016872
-------------	-----------

Board Certification

Full Name of Board	Certificate #	Dates of Certification (mm/dd/yyyy) – Start and End Dates
American Board of Urology	15419	2/28/07 –

D. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Academic positions

Title	Institution name and location	Dates held
Instructor Surgery (Urology)	Harvard Medical School Boston, MA	8/05 – 4/07
Assistant Professor Surgery (Urology)	Harvard Medical School Boston, MA	5/07 – 8/10
Associate Professor Surgery (Urology)	Harvard Medical School Boston, MA	9/10 – 3/12
Associate Professor Urology	David Geffen School of Medicine at UCLA, Los Angeles, CA	4/12 – 6/14
Professor Urology	David Geffen School of Medicine at UCLA, Los Angeles, CA	7/14 – 1/15
Professor Urology	Weill Cornell Medical College New York, NY	2/15 – 5/20
Professor with Tenure	Weill Cornell Medical College New York, NY	6/20 -

2. Hospital positions

Title	Institution name and location	Dates held
Attending Physician	Brigham and Women’s Hospital Boston, MA	8/05 – 3/12
Attending Physician	Brigham and Women’s Faulkner Hospital Boston, MA	8/05 – 3/12
Attending Physician	Ronald Reagan UCLA Medical Center Los Angeles, CA	4/12 – 1/15
Attending Physician	UCLA Medical Center Santa Monica Los Angeles, CA	4/12 – 1/15
Attending Physician	Weill Cornell Medical College New York Presbyterian Hospital New York, NY	2/15 -

E. EMPLOYMENT STATUS

Name of Employer: Weill Cornell Medical College

Employment Status: Full-time salaried by Weill Cornell

F. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation: New York Presbyterian Hospital Weill Cornell Medical College

G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES

CURRENT % EFFORT	(%)
TEACHING	0%

CLINICAL	40%
ADMINISTRATIVE	10%
RESEARCH	50%
TOTAL	100%

INSTITUTIONAL RESPONSIBILITIES

1. Teaching

<u>Didactic teaching:</u>	
Conference	
Quality Indicators for Radical Prostatectomy, Prostate Cancer SPORE seminar Dana Farber Cancer Institute, Boston, MA	2006
Current controversies in the surgical treatment of prostate cancer Lahey Clinic (AORN), Burlington, MA	2008
Current state of robotic-assisted radical prostatectomy and partial nephrectomy UCLA Santa Monica Hospital, LA, CA	2012
Controversies in diagnosing and treating prostate cancer. Health Care Partners Medical Group, Mission Hills, CA.	2012
Controversies in the screening and treatment of prostate cancer in the elderly Sixth Annual Geriatric Symposium, Asian American Medical Association and Chinese Adventist Physicians' Association, Alhambra Hospital/Medical Center	2012
Controversies in the diagnosis and treatment of prostate cancer UCLA Internal Medicine Residents' Conference	2013
UCLA-China UroExchange UCLA Ronald Reagan Medical Center	2013
Controversies in the screening and management of prostate cancer Health Care Partners Medical Group, Long Beach, CA	2013
Anatomy Lab instructor, David Geffen School of Medicine at UCLA Los Angeles, CA	2014-2015
Controversies in PSA screening. 92 nd Street Y Lecture Series. New York, New York.	2015
Controversies in PSA screening. Nomura Securities. New York, New York	2015
Controversies in PSA screening. Palmolive Colgate. New York, New York.	2015
What does the future hold for robotics in Medicine 92 nd Street Y Panel with Weill Cornell Medicine.	2016
Basic Science Localized Prostate Cancer Weill Cornell Medicine Resident Teaching Conference New York, NY	2018
Male pelvic anatomy lab lecture and video for first year medical students New York, NY	2018
3 rd International Prostate Cancer and Urologic Oncology Symposium Panel The Mount Sinai Hospital, New York, NY	2018
Basic Science Localized Prostate Cancer Weill Cornell Medicine Resident Teaching Conference New York, NY	2020

Prostate Biopsy Weill Cornell Medicine Resident Teaching Conference New York, NY	2021
---	------

Grand Rounds	
Radical Prostatectomy Outcomes, Division of Urology Grand Rounds Beth Israel Deaconess Medical Center, Boston, MA	2004
Quality Indicators for Radical Prostatectomy, Dept. of Surgery Grand Rounds Brigham and Women's Hospital, Boston, MA	2005
Trends in Prostate Cancer Diagnosis and Treatment, Dept. of Surgery Grand Rounds Faulkner Hospital, Boston, MA	2005
Recent Shifts in the Diagnosis and Treatment of Localized Prostate Cancer, Surgery Ground Rounds South Shore Hospital, Weymouth, MA	2007
Recent Shifts in the Diagnosis and Treatment of Prostate Cancer, Grand Rounds Metrowest Leonard Morse Hospital, Natick, MA	2007
Recent Shifts in the Diagnosis and Treatment of Prostate Cancer, Grand Rounds Fall River Hospital, Fall River, MA	2007
Current Controversies in the Surgical Management of Prostate Cancer, Surgery Grand Rounds South Shore Hospital, Weymouth, MA	2010
Anesthesia Considerations During Urologic Surgery, Anesthesia Ground Rounds Brigham and Women's Hospital, Boston, MA	2011
Current Controversies in the Diagnosis and Treatment of Prostate Cancer Metrowest Leonard Morse Hospital, Natick, MA	2011
Contemporary outcomes of urologic robotic surgery. UCLA Harbor Urology Grand Rounds. Torrance, CA.	2012
Improving Surgical Outcomes, UCLA Department of Urology Grand Rounds, Los Angeles, CA	2014
Robotic Surgery: Disruptive Innovation, UCLA Department of Surgery Grand Rounds, Los Angeles, CA	2014
Robotic Surgery: Disruptive Innovation, Cedars Sinai Department of Surgery noon conference, Los Angeles, CA	2014
Robotic Surgery, the next Frontier. Weill Cornell Department of Urology Grand Rounds.	2015
Current Controversies in Robotic and Minimally Invasive Surgery. Columbia College of Physicians and Surgeons Department of Urology Grand Rounds.	2015
Current Controversies in the Diagnosis and Treatment of Prostate Cancer. Weill Cornell Department of Radiation Oncology.	2016
Current Controversies in Prostate Cancer Screening and Treatment. Weill Cornell Department of Medicine.	2016

<u>Those I have mentored:</u>

Sandip Prasad, MD / BWH urology resident University of Chicago Urologic Oncology fellowship Assistant Professor, Medical University of South Carolina Garden State Urology	2007-2010
Michaela Prasad, MD / BWH urology resident Northwestern University Pediatric Urology fellowship Assistant Professor, Medical University of South Carolina Garden State Urology	2007-2010
Aaron Weinberg, BA / Boston University Medical School student Doris Duke Medical Student Research fellowship Columbia College of P&S New York Presbyterian urology residency New York University Reconstruction fellowship Chesapeake Urology	2008-2009
Paul Nguyen, MD/ Dana Farber Harvard Radiation Oncology Assistant Professor Professor, Harvard Medical School	2008-2012
Wesley Choi, MD / BWH Minimally Invasive Urologic Oncology clinical fellow Kaiser Permanente Orange County	2009-2010
Stephen Williams, MD / BWH urology resident MD Anderson Urologic Oncology fellowship Chief of Urology, University of Texas Medical Branch Galveston	2009-2011
Marcos P. Freire, MD / BWH international fellow Universidade Anhembi Morumbi, São Paulo, Brazil	2009-2010
Yin Lei, MD / BWH international fellow Associate Professor, Second Military Medical University, Shanghai, China	2010-2011
Hua-Yin Yu, MD / BWH Minimally Invasive Urology Oncology research fellow American Urologic Association Foundation research fellowship Kaiser Permanente Oakland	2010-2011
William Ulmer / Harvard Medical School student American Urologic Association Foundation, Herbert Brendler, MD Summer Medical Student Fellowship Program, David E. Rogers Fellowship, New York Academy of Medicine Albany urology residency	2010-2011
Channa Amarasekera / Harvard Medical School student Northwestern Urology residency	2010-2011
Keith J. Kowalczyk, MD / BWH Minimally Invasive Urologic Oncology clinical fellow Associate Professor, Georgetown Medical Center	2010-2011
David Friedlander / Vanderbilt medical student Harvard Longwood Urology residency UCSD Endourology fellowship	2011-2012
Andy Huang / BWH research fellow Divisions of Urology, Department of Surgery, Taipei City Hospital Associate Professor National Yang-Ming University, School of Medicine, Taiwan	2011-2012
Sunil Patel / Boston University medical student University of California at San Diego residency	2011-2012
Stacey Carter / UCLA urology resident UCLA Endourology fellowship	2012-2013

Kaiser Permanente, Los Angeles Medical Center	
Kuo-How Huang / International fellow Associate Professor National Taiwan University	2012-2013
Karim Chamie / UCLA Urologic Oncology fellow, Assistant Professor Associate Professor UCLA Urology	2012-2015
Alan Kaplan / UCLA Urology resident 3 rd place Miley B. Wesson Western Section AUA Resident Essay winner UCLA Martin Luther King Medical Center	2013-2014
Christopher Filson / UCLA Urologic Oncology fellow / Emory Urology Assistant Professor Emory	2013-2014
Ryan Chuang / UCLA medical student 2014 Herbert Brendler AUA Summer Medical Student fellowship UCLA Urology residency	2014-2015
Aaron Laviana / UCLA Urology resident Lee Resident Research Grant Vanderbilt Society for Urologic Oncology fellowship / UT Dell Medical School	2014-2015
Ray Tan / UCLA Urologic Oncology fellow Assistant Professor University of North Carolina	2014-2015
Chandan Kundavaram / UCLA Laparoscopic and Robotic Surgery fellow Academic Urology and Urogynecology of AZ	2014-2015
Eric Treat / UCLA Kidney Transplant fellow Texas Transplant Institute at Methodist Hospital, San Antonio TX	2014-2015
Padraic O'Malley / Urologic Oncology Fellow Assistant Professor, University of Florida	2014-2016
Joshua Halpern / New York Presbyterian resident Northwestern University Sexual Medicine and Reconstruction fellowship Assistant Professor Northwestern Urology	2015-2016
Jonathan Shoag / New York Presbyterian resident Weill Cornell Medicine Urologic Oncology fellowship Assistant Professor Case Western University	2015-2016
Brian Dinerman / SUNY Downstate medical student Lenox Hill Northwell Urology residency	2016-2017
Adrien Bernstein / New York Presbyterian resident Fox Chase Cancer Center Urologic Oncology fellowship	2016-2017
Ron Golan / New York Presbyterian resident Columbia New York Presbyterian Endourology fellowship	2016-2017
Eliza Cricco-Lizza / Weill Cornell medical student Ferdinand C. Valentine Fellowship Award for Research in Urology New York Academy of Medicine Brigham and Women's Internal Medicine residency	2016-2017
Khushabu Kasabwala / New York Presbyterian resident University of Minnesota Reconstruction fellowship / Lahey Clinic Assistant Professor	2017-2018
Neal Patel / New York Presbyterian resident UCLA Urologic Oncology fellowship	2017-2018

Soo Kim / New York Presbyterian resident Texas Childrens' Pediatric Urology fellowship	2017-2018
Benjamin Taylor / SUO fellow Garden State Urology	2018-2019
Andre Ruan Belarmino / Weill Cornell medical student UCLA Urology residency	2018-2019
Michael Gross / Stony Brook medical student Cleveland Clinic Urology residency	2018-2019
Shokhi Goel / Weill Cornell medical student Mount Sinai Urology residency	2018-2019
Bashir Al Hussein Al Awamlh / New York Presbyterian resident/Vanderbilt Urologic Oncology Fellowship	2019-2020
Mark Alshak / Weill Cornell medical student/ Johns Hopkins Urology Residency	2018-2019
Michael Tzeng / Weill Cornell medical student	2018-present
Spyridon Basourakos / New York Presbyterian resident	2019-present
Ashwin Ramaswamy / New York Presbyterian resident	2019-present
Meenakshi Davuluri / Weill Cornell Clinical Instructor	2020-present
John Graham / Weill Cornell Assistant Professor	2020-present
Emily Cheng / Weill Cornell medical student	2020-present

<u>Clinical teaching:</u>	
Robotic Surgery, Quality of life in bladder cancer, Health services research in urology Urologic Cancer Course, Dana Farber/Brigham and Women's Harvard Cancer Center	2006, 2008
Surgical approach to treatment of prostate cancer Advances in the Treatment of Genitourinary Cancer, Dana Farber Cancer Institute, Dana Farber Cancer Institute	2008
Comparative Effectiveness of minimally invasive vs. open radical prostatectomy University of Florida Comparative Effectiveness and Evidence Based Medicine	2010
Robotic Assisted Laparoscopic Radical Prostatectomy: Quality of Life and Beyond 10 th International Congress on GU Malignancies	2010
Workshop for Robotic-Assisted Surgery: step-by-step approach to radical prostatectomy UCLA State of the Art Urology	2012
Technical Modifications during radical prostatectomy to maximize urinary and sexual function UCLA State of the Art Urology	2012
Controversies in Screening and Treating prostate cancer in the Elderly 29 th Annual Intensive Course in Geriatric Medicine and Pharmacy, UCLA Multi-campus Program in Geriatric Medicine and Gerontology	2012
Maximizing continence and potency during radical prostatectomy, Comparative effectiveness and costs of robotic, laparoscopic and open urologic surgery Kaiser Urology Symposium	2012

Workshop for Robotic-Assisted Partial nephrectomy: step-by-step approach.	2013
Indications and Limitations to Robotic-Assisted Partial Nephrectomy	2013
Controversies in the Screening and Management of Prostate Cancer UCLA Primary Care Update 2013	2013
UC Irvine Renal Tumor Management Course	2014
Jackson Hole Seminars	2014
World Congress of Endourology Educational Course, Robotic Radical Prostatectomy: the Step by Step Approach	2014

Administrative teaching leadership role:	
Co-Director UCLA Center for Advanced Surgical and Interventional Technology	2012-13
Chair- ad hoc review and appraisal promotions committee UCLA Academic Senate	2013
Co-Chair, Surgical Services Robotic Surgery Sub-committee UCLA Medical Center	2014-15
New York Presbyterian Weill Cornell representative for the American College of Surgeons Cancer Liaison Program	2016-2019

2. Clinical care

Clinical Activity; Clinical Program Development	Dates
Multi-disciplinary Genitourinary Oncology Clinic Dana Farber Cancer Institute	0.5 days a week, 8/05 – 3/12
Robotic-assisted laparoscopic surgery at Brigham and Women's Faulkner Hospital	2 days a week, 8/05 – 3/12
Robotic-assisted laparoscopic surgery at Brigham and Women's Hospital	8/05 – 3/12
Urologic oncology clinic at Brigham and Women's Hospital	1 day a week, 8/05 – 3/12
Donor Nephrectomy surgery at UCLA Ronald Reagan Medical Center	1 day a week, 4/12 – 1/15
Kidney transplant clinic at UCLA Ronald Reagan Medical Center	0.25 days a week, 4/12 – 1/15
Urologic oncology clinic at UCLA Ronald Reagan Medical Center	0.75 days a week, 4/12 – 1/15
Surgery at UCLA Ronald Reagan Medical Center	1 day a week, 4/12 – 1/15
Surgery at UCLA Santa Monica Medical Center	1 day a week, 4/12 – 1/15
Surgery at Weill Cornell New York Presbyterian	2 days a week, 2/15 –
Urologic Oncology Clinic at Weill Cornell New York Presbyterian	2 days a week, 2/15 –

3. Research

Research Activity / Key Contributions	Dates
Brigham and Women's Center for Surgery and Public Health	2005-12

4. Administrative Activities

Administrative Activity	Date
Compliance Committee, Brigham and Women's Hospital	2005-07
Ambulatory Committee, Brigham and Women's Hospital	2008-09
Robotic Surgery Committee, Brigham and Women's Hospital	2009-12
Urology Quality Assessment Committee, UCLA Medical Center	2012-13
Co-Director UCLA Center for Advanced Surgical and Interventional Technology	2012-13
UCLA Faculty Practice Group Committee, UCLA Medical Center	2012-13
Surgical Services Robotic Surgery Sub-committee, UCLA Medical Center	2012-14
Internal Advisory Committee, UCLA Center for World Health	2013
Chair- ad hoc review and appraisal promotions committee UCLA Academic Senate	2013
Co-Chair, Surgical Services Robotic Surgery Sub-committee UCLA Medical Center	2014-15
Weill Cornell New York Presbyterian Robotic Surgery Committee	2015-present
Director of LeFrak Center for Robotic Surgery	2015-present
Co-Leader, Weill Cornell Medicine Prostate Cancer Disease Management Team	2018-2019
Weill Cornell Medicine Medical School Admissions Committee	2020-2021
Grand Rounds Course Director, Weill Cornell Department of Urology	2020-present
Quality and Patient Safety Chair, Weill Cornell Department of Urology	2020-Present
Weill Cornell Medicine Physician Well-Being Task Force	2020-present
Weill Cornell Medicine Committee of Review for Faculty Appointment, Promotion and Tenure	2022-2023

H. RESEARCH SUPPORT

Past Research:

2007-09	Lance Armstrong Foundation Young Investigator Award (PI 50%) \$110,000, Patterns of care of minimally invasive radical prostatectomy
2007-08	Dana Farber / Harvard Cancer Center Prostate Cancer SPORE Career Development Award (PI, 25%) \$60,000. Quality of life and outcomes of radical prostatectomy

2008-13	Department of Defense Physician Training Award W81XWH-08-1-0283 (PI, 50%) \$560,000. Patterns of care, utilization, and outcomes of treatments for localized prostate cancer
2009-11	NIH RC1 EB011001-01 (Co-I, 3%) \$24,000. Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
2009-11	NIH RC1 CA146596-01 (Co-I, 3%) \$24,000, Effectiveness of Early Stage Prostate Cancer Treatment
2010-11	Dana Farber Kidney Cancer SPORE Director's Choice Award (Co-I, 5%) \$10,000, Comparative Effectiveness of Therapies for Localized Kidney Cancer
2011-12	U.S. Army Medical Research Acquisition Activity / Center for Integration of Medicine and Innovative Technology No. 11-325W81XWH-09-2-0001 (Co-I, 3%) \$3,800, Robot-assisted laparoscopic prostatectomy guided by patient-specific models
2017-19	NIH 5-U01 CA086402-18 (Subsite PI, 10%), San Antonio Center for Biomarkers of Risk for Prostate Cancer (SABOR)
2017-19	NIH 5-R01 CA 207216 (Co-I, 8%), Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and Costs
2017	NIH 1-R01 CA 218547-01 (mPI, 5%), \$627,518, Focal Laser Ablation of Prostate Cancer Using MR/US Fusion

Current Research Support:

Source	National Institutes of Health R01 CA241758 Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection
Amount	\$680,080 direct costs annually
Duration	9/11/2020 – 06/30/2025
Principal Investigator	Hu JC, Weill Cornell Medicine; Schaeffer EM, Northwestern University; Allaf M, Johns Hopkins
Your Role in Project	Principal Investigator
% Effort	20% x 5 years

Source	Patient-Centered Outcomes Research Institute (PCORI) – Assessment of Prevention, Diagnosis and Treatment Options CER-2019C1-15682 Prostate Cancer Comparative Outcomes of New Conceptual Paradigms for Treatment (PC CONCEPT)
Amount	\$1,003,431 direct costs annually for 5 sites
Duration	11/01/2020 – 11/30/2024
Principal Investigator	Hu JC, Weill Cornell Medicine; Chen RC, University of Kansas
Your Role in Project	Principal Investigator

% Effort	15% x 3 years
----------	---------------

Source	Prostate Cancer Challenge Award Construction of a cloud-based integrated experimental and clinical database of a primary and metastatic prostate cancer cohort
Amount	\$50,000 direct costs annually
Duration	12/30/2020 – 12/30/2025
Principal Investigator	Hu, JC
Your Role in Project	Principal Investigator

Source	Patient-Centered Outcomes Research Institute (PCORI) – Assessment of Prevention, Diagnosis and Treatment Options CER-2019C2-17372 Randomized Trial Comparing Transperineal vs. Transrectal MRI-targeted Prostate Biopsy
Amount	\$1,258,985 direct costs annually for 12 sites
Duration	04/01/2021 – 04/30/2025
Principal Investigator	Hu JC, Weill Cornell Medicine; Schaeffer EM, Northwestern University
Your Role in Project	Principal Investigator
% Effort	15% x 3 years

Source	National Institutes of Health R01 CA249615 Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost (SBRT-SIB) for High-Risk Prostate Cancer
Amount	\$4,983 direct costs for Project Year 2
Duration	07/01/2021 – 06/30/2021
Principal Investigator	Kang J, Weill Cornell Medicine
Your Role in Project	Co-Investigator
% Effort	2.5%

Source	National Institutes of Health R01 CA259173-01A1 Pelvic fascia spARing radical prostatectomy TRIAL (PARTIAL)
Amount	\$3,354,585 direct costs
Duration	2/01/2022 – 01/31/2027
Principal Investigator	Hu, JC
Your Role in Project	Principal Investigator

Source	National Institutes of Health R01 CA273031 Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic Prostatectomy
Amount	Pending
Percentile	12%; Impact score: 29
Duration	7/01/2022 – 06/30/2027
Principal Investigator	Hu, JC; Hung, A (contact)
Your Role in Project	Principal Investigator

I. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Activity / Responsibility	Dates
Scientific Committee Co-Chair, New England Urological Association	2009
Scientific Committee, New England Urological Association	2010
Grant Review Committee, American Urological Association Foundation Research Scholars	2010
Grant Review Committee, American Urological Association Foundation Research Scholars	2011
Prostate Cancer Planning Committee, Society of Urologic Oncology	2011
International Academic Fellowship Committee, American Urological Association	2011-16
Prostate Cancer Planning Committee, Society of Urologic Oncology	2012
Grant Review Committee, American Urological Association Foundation Research Scholars	2012
Grant Review Committee, Urology Care Foundation/Astellas Rising Star in Urology Research Awards	2013
Grant Reviewer, Robotic Telesurgery Research, US Army Medical Research and Materiel Command	2013
Grant Reviewer, Cancer Research UK Science Committee	2014
American Urologic Association, Practice Guideline Committee	2015-present
American Urologic Association, Video Education Committee	2015-present
Grant Review Committee, American Urological Association Foundation Research Scholars	2015
Grant Review Committee, Department of Defense Congressionally Directed Medical Research Programs Prostate Cancer Research Program Prevention, Therapy, Epidemiology (PTE) peer review panel	2015
American Urological Association, Laparoscopic, Robotic and New Surgical Technologies (LRNST) Committee	2016-present
American Urological Association Professional Guidelines Committee	2016-present
Chair of Grant Review Committee for Prostate Cancer Canada, Special Project in Non-Metastatic Castrate Resistant Prostate Cancer	2016
Grant Review Committee, Center for Scientific Review	2016
Grant Review Committee, Surgical Sciences, Biomedical Imaging Bioengineering Small Business Study Section (SBIB-H56)	2016
American Board of Urology Examination Committee	2016-present
Grant Review Committee, Center for Scientific Review Special Emphasis Panel, Center for Scientific Review – Early Phase Clinical Trials in Imaging and Image-Guided Interventions Agenda	2017
NIH Grant Review Committee, Surgical Sciences, Biomedical Imaging Bioengineering Small Business Study Section (SBIB-S59)	2017
NIH Grant Review Committee, Surgical Sciences, Biomedical Imaging Bioengineering Small Business Study Section (SBIB-H56)	2017
Grant Reviewer, 2017 Research Innovation Awards Second Stage, Prostate Cancer UK	2018

Associate Editor, British Medical Journal, Interventions & Health Technologies	2019-present
--	--------------

Invited Presentations and Courses – Regional	
Utilization and Outcomes of Minimally Invasive Radical Prostatectomy, Grand Rounds University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY	2008
Moderator – Concurrent scientific session VI: Novel surgical techniques/laparoscopy/robotics New England American Urological Association Annual Meeting, Rio Grande, Puerto Rico	2008
Moderator – Video session New England American Urological Association Annual Meeting, Washington D.C.	2009
Current Controversies in the Surgical Treatment of Prostate Cancer New England Urological Association Town Hall/Socio-Economic Forum, Boston, MA	2010
The Case for Definitive Treatment Versus Active Surveillance for Low Risk Prostate Cancer: Point/Counterpoint New England American Urological Association Annual Meeting, Providence, RI	2010
The Case for Adjuvant versus Salvage Radiotherapy Following Radical Prostatectomy: Point/Counterpoint, New England/Mid-Atlantic American Urological Association Annual Meeting, Orlando, FL	2011
Moderator – Prostate Cancer 2 Session Western Section American Urological Association Annual Meeting, Waikoloa, HI	2012
Use, outcomes and technique for urologic robotic surgery University of California Irvine Urology Grand Rounds	2013
Current Controversies in Robotic Assisted Surgery Yale Department of Urology Grand Rounds	2016
Current Controversies in the Diagnosis and Treatment of Prostate Cancer, Department of Urology Georgetown School of Medicine	2016
Weill Cornell Medicine Department of Healthcare Research and Policy Grand Rounds, New York, NY	2017
Us Too Prostate Cancer Support Group	2017
IDEAL International Conference 2017: Research, Regulation, and Reimbursement in Surgery and Technologies New York, NY	2017
Comparative Effectiveness Research in Prostate Cancer International Prostate Forum American Urological Association (AUA) 2017 Annual Meeting Boston, MA	2017

Current Controversies in the Diagnosis and Treatment of Prostate Cancer University of Rochester Urology Grand Rounds	2017
Current Controversies in the Diagnosis and Treatment of Prostate Cancer SPORE Working Group New York, NY	2019
Moderator – Population Science and Outcomes Research section, 13 th Annual Prostate Cancer Program Retreat Fort Lauderdale, FL	2020
Anatomic and Technical Considerations for Prostate and Kidney Surgery NYS EMPIRE Urology Lecture Series New York, NY	2020
Current Controversies in Prostate Cancer Diagnosis and Treatment Mt. Sinai Urology Grand Rounds	2020
Current Controversies in Prostate Cancer Diagnosis and Treatment Weill Cornell Medicine Grand Rounds	2020
Controversies in Prostate Cancer Diagnosis and Treatment Maimonides Medical Center Department of Surgery Ground Rounds	2021
Controversies in the Diagnosis and Treatment of Prostate Cancer Memorial Sloan Kettering Cancer Center Population Sciences Research Program	2021

Invited Presentations and Courses – National	
Radical Prostatectomy Outcomes, Urology Grand Rounds University of Miami School of Medicine, Miami FL	2004
Quality Indicators For Radical Prostatectomy, Genitourinary Research Conference Memorial Sloan Kettering, NYC, NY	2006
Quality Indicators in Radical Prostatectomy, Urology Grand Rounds Roswell Park Cancer Center, Buffalo, NY	2006
Peri-operative Outcomes of Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy, Society for Urologic Oncology Young Investigators Forum, Bethesda, MD	2007
Quality of Care of Radical Prostatectomy, Urology Grand Rounds Stanford Cancer Center, Palo Alto, CA	2008
Controversies Regarding the Surgical Management of Prostate Cancer, Urology Grand Rounds Johns Hopkins Brady Department of Urology, Baltimore, MD	2009
Comparative Effectiveness of Open vs. Minimally Invasive Radical Prostatectomy, Podium presentation American Urological Association Foundation Young Investigator Forum, San Francisco, CA	2010
Current controversies in the surgical management of prostate cancer Hans Shapira Visiting Professor, Mount Sinai Department of Urology, NYC, NY	2010
Radical Prostatectomy: Technology versus Technique	2010

Duke University School of Medicine, Division of Urology Grand Rounds, Durham, NC	
Radical Prostatectomy: Technology versus Technique Massachusetts General Hospital Cancer Center Conference, Boston, MA	2010
Plenary Take Home Message for Outcomes Analyses American Urological Association Annual Meeting. Washington DC	2011
Current and future role for urologic robotic surgery UCLA Department of Urology Grand Rounds, Los Angeles, CA	2011
American Academy of Pediatrics Section on Urology Panel: Clinical Research in Pediatric Urology: the Need, the Challenge, and the Way Forward	2011
Utilization, technique and outcomes of urologic robotic surgery University of Washington Department of Urology, Seattle, WA	2012
Quality of evidence in robotic assisted radical prostatectomy Society of Urological Robotic Surgery Annual Meeting, Atlanta, GA	2012
Moderator – Prostate cancer: localized I (podium) American Urological Association Annual Meeting, Atlanta, GA	2012
National Cancer Policy Forum Workshop on Delivering Affordable Cancer Care in the 21 st Century: New Technologies in Surgery Institute of Medicine of the National Academies, Washington DC	2012
Moderator – Prostate Session II: Part 2: Survivorship Society of Urologic Oncology, Bethesda, MD	2012
Moderator – General & Epidemiological Trends & Socioeconomics: Quality of Life Moderated Poster American Urological Association Annual Meeting. San Diego, CA	2013
Critical Maneuvers During Radical Prostatectomy to Preserve Sexual and Urinary Function. Korean World Urologic Congress, American Urological Association Annual Meeting. San Diego, CA	2013
Plenary Session: Point-Counterpoint: Using Donors with Hypertension, Obesity, Lap Right Kidneys, American Urological Association Annual Meeting. Orlando, FL	2014
Utilization and Outcomes of Robotic Assisted Surgery: a Disruptive Technology. James Buchanan Brady Foundation Department of Urology Grand Rounds, Weill Cornell Medical College. New York City, New York.	2014
Vascular Control with Stapling During Live Donor Nephrectomy. Egyptian Urological and American Urological Association Joint Meeting. New Orleans, LA.	2015
Comparative Effectiveness Research of Robotic Surgery for Cancer Therapy. National Cancer Policy Forum Workshop on Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology at the Institute of Medicine at the National Academies, Washington D.C.	2015
Moderator – Benign Robotic Surgery Video Session. American Urological Association Annual Meeting. San Diego, CA	2016
Current Controversies in Robotic Surgery. Society of Urologic Robotic Surgeons at the American Urological Association Annual Meeting. San Diego, CA	2016

Study of Prostate Ablation Related Energy Devices (SPARED) Think Tank Meeting, Washington DC	2016
Current Controversies in the Diagnosis and Management of Prostate Cancer University of Miami Grand Rounds, Miami, FL	2017
Prostate Cancer Best of Journals 2017 Genitourinary Cancers Symposium (ASCO GU) Orlando, FL	2017
Site Anatomy & 8 th Edition Staging: Prostate; National Cancer Registrars Association Alexandria, VA	2017
Controversies in Prostate Cancer Screening 2 nd International Prostate Cancer Symposium & Inaugural World Congress of Robotic Urologic Oncology Mt Sinai Medical Center, New York, NY	2017
Study of Prostate Ablation Related Energy Devices (SPARED) Think Tank Meeting, Washington DC	2017
After Brigham: From Kidneys in LA to Controversies in NY Brigham and Women's Hospital Urology Research Conference Boston, MA	2018
Study of Prostate Ablation Related Energy Devices (SPARED) Think Tank Meeting, Washington DC	2018
FDA Advisory Committee: Center for Drug Evaluation and Research, Washington DC	2018
Study of Prostate Ablation Related Energy Devices (SPARED) Meeting, Washington DC	2018
After Brigham: From Kidneys in LA to Controversies in NY Johns Hopkins Brady Urology Grand Rounds Baltimore, MD	2018
University of Texas Medical Branch, Earl W. Clawater Visiting Professor Lectureship Galveston, TX	2018
Active Surveillance for Prostate Cancer, Keynote Speaker Pennsylvania Prostate Cancer Conference Penn State College of Medicine Hershey, PA	2018
Medstar Georgetown Urology Visiting Professor Washington DC	2018
AdMeTech Foundation, Fourth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer Boston, MA	2019
SPARED Prostate: Evaluating Safety and Efficacy of Cancer Ablation Devices 10 th MDEpiNet Annual Meeting: Addressing Challenges in National and Global Health Technology Research and Surveillance Washington DC	2019
Point Counterpoint: Index Lesion Ablation Achieves Oncological Control in Prostate Cancer	2019

FOCAL 2019: Frontiers in Oncologic Prostate Care and Ablative Local Therapy Miami, FL	
Update on Contemporary Partial Cryoablation Technique and Outcomes: What's the Evidence? FOCAL 2019: Frontiers in Oncologic Prostate Care and Ablative Local Therapy Miami, FL	2019
Value, Vector, Vision UCSD Urology Grand Rounds	2019
Contemporary Diagnosis and Treatment of Localized Prostate Cancer FDA Oncologic Drugs Advisory Committee: Center for Drug Evaluation and Research Washington DC	2020
Moderator – Prostate Cancer: Localized: Surgical Therapy I American Urological Association Annual Meeting Washington DC	2020
Anatomic and Technical Considerations for Prostate and Kidney Surgery USCF Urologic Collaborative Video Didactics (COVID)	2020
Moderator – 13 th Annual Prostate Cancer SPORE Retreat Ft Lauderdale, FL	2020
Racial Disparities in Continence After Radical Prostatectomy Moderated poster, American Urological Association Annual Meeting	2020
Study of Prostate Ablation Related Energy Devices (SPARED) collaboration Society of Urologic Oncology Annual Spring Meeting	2020
Active Surveillance of Medical Device Safety and Outcomes using EHRs: Prostate Cancer Partial Gland Ablation Technologies Johns Hopkins University CERSI Semi-Annual Program	2020
Current Controversies in the Diagnosis and Treatment of Prostate Cancer Advanced Urology Journal Club, Atlanta GA	2020
El reto del TREFIT y la biopsia transperineal sin antibióticos: Un ensayo clínico multi-institucional Congreso de la Confederación Americana de Urología (CAU)	2020
Overview of Image-Guided, Minimally-Invasive Focal Treatment AdMeTech Foundation, Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer	2020
Current Controversies in Prostate Cancer Diagnosis and Treatment Cedars-Sinai Department of Urology Grand Rounds	2020
Current Controversies in Prostate Cancer Diagnosis and Treatment University of Michigan Urology Grand Rounds	2020
SUO 2020: Transperineal Prostate Biopsy Update Society of Urologic Oncology 21 st Annual Meeting	2020
Urologic Perspective on Clinical Utility and Outcomes AdMeTech Foundation, Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer	2021

Moderator – Cancer Outcomes Sessions of Developing Provocative Questions: The Prostate Cancer Active Surveillance Research Initiative	2021
PCORI 2021: PCORI's Approaches to New Technologies: Keeping Up with Health Care Innovations: Prostate Cancer Comparative Outcomes of New Conceptual Paradigms for Treatment Patient-Centered Outcomes Research Institute 2021 Annual Meeting	2021
Developing Provocative Questions: The Prostate Cancer Active Surveillance Research Initiative The Patients Program at the University of Maryland School of Pharmacy	2021
SUO 2022: Prostate Cancer Webinar Society of Urologic Oncology Education Committee Webinar	2022
Moderator – Prostate Cancer: Localized Surgical Therapy I American Urological Association (AUA) 2022 Annual Meeting New Orleans, LA	2022
Overcoming the Learning Curve for Retzius-Sparing Prostatectomy Instructional Course American Urological Association (AUA) 2022 Annual Meeting New Orleans, LA	2022

Invited Presentations and Courses – International	
Live surgery demonstration of robotic assisted radical prostatectomy Triservice General Hospital, Taipei, Taiwan	2005
Evolution of radical prostatectomy West China University, Chengdu, China	2005
Evolution of radical prostatectomy Taipei City Hospital, Taipei, Taiwan	2005
U.S. medical school, residency and fellowship education from an academic urology perspective Taipei City Hospital, Taipei, Taiwan	2005
Recent Shifts in the Diagnosis and Treatment of Prostate Cancer Arab Health Fair, Dubai, United Arab Emirates	2007
Update on Robotic Assisted Laparoscopic Radical Prostatectomy Techniques, Grand Rounds Taipei City Hospital, Zhong Xiao Branch, Taipei, Taiwan	2009
Update on Robotic Assisted Laparoscopic Radical Prostatectomy Techniques, Grand Rounds Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan	2009
Technical Modifications of Robotic Assisted Laparoscopic Radical Prostatectomy and Live Demonstration of Robotic Assisted Laparoscopic Radical Prostatectomy Asian Congress of Urology, Taipei, Taiwan	2010
Current Controversies Regarding Radical Prostatectomy in the U.S. Asian Congress of Urology, Taipei, Taiwan	2010
American medical school, residency and fellowship education from an academic urology perspective	2010

Second Military Medical University, Shanghai, China	
Comparative effectiveness of minimally invasive versus open radical prostatectomy Changhai Hospital, Shanghai, China	2010
Live surgery demonstration of laparoscopic radical prostatectomy Changhai Hospital, Shanghai, China	2010
Radical Prostatectomy: Technology versus Technique Chinese Urological Association and American Urological Association Resident Education Course Xi'An, China	2010
Technical Refinement of Robotic-Assisted Laparoscopic Radical Prostatectomy: Overcoming the Learning Curve Chinese Urological Association Annual Meeting, Xi'An, China	2010
Radical Prostatectomy: Technology versus Technique and live demonstration of Laparoscopic Radical Prostatectomy Changhai Hospital Department of Urology, Shanghai, China	2010
Maximizing recovery of erectile function following robotic assisted radical prostatectomy Conjoint Meeting of East Asian Society of Endourology and Asian Society of Endourology, Taipei, Taiwan	2012
Critical Maneuvers During Robotic Assisted Radical Prostatectomy to Preserve Urinary and Sexual Function Taiwan Urological Association Annual Meeting, Taipei, Taiwan	2012
Evidence and Technique for Robotic Assisted Radical Prostatectomy Reconstruction and Anastomosis Asian Robotic Urological Symposium (ARUS), Taipei, Taiwan	2012
Apical Dissection During Robotic Assisted Radical Prostatectomy – Maximizing functional and cancer control outcomes Asian Robotic Urological Symposium (ARUS), Taipei, Taiwan	2012
Moderator – Robotic partial nephrectomy session Asian Robotic Urological Symposium (ARUS), Taipei, Taiwan	2012
Live surgery demonstration: robotic-assisted retroperitoneal partial nephrectomy Live surgery demonstration: robotic-assisted extraperitoneal radical prostatectomy Kaohsiung Veteran General Hospital, Kaohsiung, Taiwan	2013
Robotic-assisted surgery for renal cortical tumors Kaohsiung Veteran General Hospital, Kaohsiung, Taiwan	2013
Robotic-Assisted Laparoscopic Radical Prostatectomy in 2014 Chinese Endourology Forum, Taipei, Taiwan	2014
Expert Video Discussion – Robotic Radical Prostatectomy World Congress of Endourology, Taipei, Taiwan	2014
Moderator – New robotic technology World Congress of Endourology, Taipei, Taiwan	2014
European Urology Forum 2015 Challenge the Experts, Davos Switzerland Prostate Cancer Screening and Treatment in the Elderly Minimally Invasive Surgery for Renal Cancer	2015

Moderator for 3 Challenger panels	
(1) Medical Treatment of Metastatic Renal Cell Carcinoma; (2) Contemporary Classification of Renal Tumors; (3) Evolving Imaging of GU Cancers. Salzburg ESU/Weill Cornell Master Class In Urology	2016
(1) Current Controversies in the Diagnosis of Prostate Cancer; (2) Technical Modifications to Improve Radical Prostatectomy Outcomes. 1 st Oriental Congress of Urology and Andrology (OCUA 2016) & Annual meeting of Shanghai Urology and Andrology Association	2016
Live Surgery, Retroperitoneal Partial Nephrectomy, Department of Urology, Zhejiang University First Hospital, Hangzhou, China	2016
High Intensity Focused Ultrasound, Novelty or Innovation? 5 th International Symposium on Focused Ultrasound, Bethesda, MD	2016
Prostate cancer screening controversy and contemporary practice New York AUA Section Annual Meeting, Prague, Czech Republic	2016
Challenges in MRI Ultrasound Fusion Guided Biopsy and Therapy NY AUA Section Annual Meeting, Havana, Cuba	2017
Current controversies in the Diagnosis and Treatment of Prostate Cancer International Forum on Urology, Shanghai, China	2017
Image guided Biopsy and Treatment for Prostate Cancer Taiwan Urological Association Annual Meeting, Taipei, Taiwan	2018
Current Controversies in the Diagnosis and Treatment of Prostate Cancer National Taiwan University	2018
1 st Hands-On Transperineal Prostate Biopsy Workshop Department of Surgery, University of Hong Kong Queen Mary Hospital	2018
Live Surgery Demonstration and Presentation Nanjing Drum Tower Hospital	2018
Office Based Prostate Cancer Therapy New York AUA Section Annual Meeting, Nice, France	2019
Presentation: MRI-Ultrasound Fusion Targeted Transperineal Prostate Biopsy Vestfold Hospital Trust, Tønsberg, Norway	2019
Presentation: MRI-Ultrasound Fusion Targeted In-Office Partial Gland Cryoablation Vestfold Hospital Trust, Tønsberg, Norway	2019
Live demonstration & workshop: MRI-Ultrasound Fusion Targeted Transperineal Prostate Biopsy Vestfold Hospital Trust, Tønsberg, Norway	2019
New York AUA Section Annual Meeting, Nice, France	2019
Current Controversies in the Diagnosis and Treatment of Prostate Cancer Disciplina de Urologia Centro Universitários Saúde ABC	2020
PSA Screening Controversy Guangdong Province Urology Association Annual Meeting	2021

J. PROFESSIONAL MEMBERSHIPS

Member	Organization	Dates
Member	American Urologic Association	4/01 – present
Member	Society of Urologic Oncology	8/06 – present
Member	Society of Endourology	5/08 – present
Member	Western Section AUA	4/12 – 3/16
Member	New York City Section AUA	2/15 – present

K. HONORS AND AWARDS

Name of award	Date awarded
Johns Hopkins University Department of Economics – Graduated with Honors	1993
American Foundation for Urologic Disease Medical Student Summer Fellowship	1997
Arnold Award Outstanding Medical Student, Scott Department of Urology Baylor College of Medicine	1998
American Cancer Society Medical Student Fellowship	1998
CaPSURE Scholar, UCSF/UCLA	2002-04
Third Place, Los Angeles Urologic Association Resident Essay Contest	2002
Second Place, Miley B. Wesson Resident Essay Contest, Western Section AUA	2002
Second Place, Joseph F. McCarthy Physician Essay Contest, Western Section AUA	2005
Clinical Innovation Award, Brigham and Women’s Physicians Organization	2008
Best Poster, Epidemiological Trends and Socioeconomics Session, American Urologic Association Annual Meeting	2008
Brigham Leadership Program, Harvard Business School	2009
Academic Exchange Scholar, American Urologic Association/Chinese Urologic Association	2010
Best Doctors, US News and World Report	2011-14
Top Doctors, Castle Connolly	2012-15
Henry Singleton Chair in Minimally Invasive Surgery, UCLA Medical Center	2012-15
Super Doctors, Los Angeles Magazine / Key Professional Media	2013-15
Top Prostate Cancer Specialists, Castle Connolly	2014-18
Third Place, Jackson Hole Seminars	2014
First Place, History of Urology Western Section, AUA	2014
Third Place, Joseph F McCarthy Physician Essay Contest	2014
Ronald P. Lynch Chair in Urologic Oncology	2015 – present
Best Poster, Society of Urologic Oncology Bethesda, MD	2015
Best Poster, American Urological Association Boston, MA	2017
Best Poster, European Urological Association Copenhagen, DK	2018

L. BIBLIOGRAPHY

Highlighted publications

1. **Hu JC**, Gu X, Lipsitz SR, Barry MJ, D'Amico AV, Weinberg AC, Keating NL. Comparative effectiveness of minimally invasive vs open radical prostatectomy. *JAMA*. 2009;302(14):1557-64.
2. Nguyen PL, Je Y, Schutz F, Hoffman KE, **Hu JC**, Parekh A, Beckman JA, Choueiri TK. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *JAMA*. 2011;306(21):2359-2366.
3. Freire MP, Weinberg AC, Lei Y, Soukup JR, Lipsitz SR, Prasad SM, Korkes F, Lin T, **Hu JC**. Anatomic Bladder Neck Preservation During Robotic-Assisted Laparoscopic Radical Prostatectomy: Description of Technique and Outcomes. *Eur Urol*. 2009; 56(6): 972-80.
4. **Hu JC**, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. *J Clin Oncol*. 2003;21(3):401-5.
5. Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, **Hu JC**. Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. *J Clin Oncol*. 2011 Apr 20;29(12):1517-24.
6. Yu H, Hevelone ND, Lipsitz SR, Kowalczyk KJ, **Hu JC**. Use, costs and comparative effectiveness of robotic-assisted, laparoscopic, and open urologic surgery. *J Urol*. 2012. Apr;187(4):1392-8.
7. Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Trinh QD, **Hu JC**, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. *Cancer*. 2014 May 15;120(10):1532-9.
8. Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, Choueiri TK, Kibel AS, **Hu JC**. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. *Eur Urol*. 2012 Jun;61(6):1239-44.
9. Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, **Hu JC**, Shariat SF, Sun M, Vickers AJ. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol*. 2013 Nov;64(5):786-98.
10. **Hu JC**, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. *J Clin Oncol*. 2008;26(14):2278-84.
11. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, **Hu JC**, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-targeted or standard biopsy for prostate-cancer diagnosis. *N Engl J Med*. 2018 Mar 18. Doi: 10.1056/NEJMoa1801993.
12. **Hu JC**, Gandaglia G, Nguyen PL, Trinh Q-D, Shih Y-CT, Abdollah F, Chamie K, Wright JL, Karakiewicz PI, Ganz PA, Sun M. Comparative effectiveness of robotic-assisted versus open radical prostatectomy cancer control. *Euro Urol*. 2014 Oct;66(4):666-72.
13. **Hu JC**, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, Marks LS. Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply? *J Urol*. 2014 Aug;192(2):385-90.
14. **Hu JC**, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. *J Urol*. 2003;169(6):2279-83.

15. Al Hussein Al Awamlh B, Ma X, Christos P, **Hu JC**, Shoag JE. Active Surveillance for Black Men with Low-Risk Prostate Cancer in the United States. *N Engl J Med*. 2019 Dec 26;381(26):2581-2582. Doi: 10.1056/NEJMc1912868.
16. Shoag JE, Nyame Y, Gulati R, Etzioni R, **Hu JC**. Reconsidering the Tradeoffs of Prostate Cancer Screening. *N Engl J Med*. 2020 Jun 18;382(25):2465-2468. Doi: 10.1056/NEJMs2000250.
17. Shoag JE, Mittal S, **Hu JC**. More on Reevaluating PSA Testing Rates in the PLCO Trial. *N Engl J Med*. 2016 Oct 13;375(15):1500-1501. Doi: 10.1056/NEJMc1607379.
18. **Hu JC**, Laviana A, Sedrakyan A. High-Intensity Focused Ultrasound for Prostate Cancer: Novelty or Innovation? *JAMA*. 2016 Jun 28;315(24):2659-60. Doi:10.1001/jama.2016.5002.
19. Halpern JA, Shoag JE, Artis AS, Ballman KV, Sedrakyan A, Hershman DL, Wright JD, Shih YC, **Hu JC**. National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the United States Preventative Services Task Force Guidelines Against Prostate-Specific Antigen Screening. *JAMA Surg*. 2016 Nov 2. Doi: 10.1001/jamasurg.2016.3987.
20. Chamie K, Williams SB, **Hu JC**. Population-Based Assessment of Determining Treatments for Prostate Cancer. *JAMA Oncol*. 2015 Apr;1(1):60-7. Doi: 10.1001/jamaoncol.2014.192.
21. Kim SJ, Vickers AJ, **Hu JC**. Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening. *JAMA Oncol*. 2018 Sep. doi:10.1001/jamaoncol.2018.4160
22. **Hu JC**, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, Sedrakyan A. Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. *JAMA Oncol*. 2016 Dec 29. Doi: 10.1001/jamaoncol.2016.5465.
23. Borregales LD, DeMeo G, Gu X, Cheng E, Dudley V, Schaeffer EM, Nagar H, Carlsson S, Vickers A, **Hu JC**. Grade Migration of Prostate Cancer in the United States during the last decade [published online ahead of print, 2022 Mar 28]. *J Natl Cancer Inst*. 2022;djac066. doi:10.1093/jnci/djac066
24. Basourakos, S., Gulati, R., Vince, R., Spratt, D., Lewicki, P., Hill, A., Nyame, Y., Cullen, J., Markt, S., Barbieri, C., Hu, J., Trapl, E. and Shoag, J. Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men [published online ahead of print, 2022 May 15]. *NEJM Evidence*,. 2022. DOI:<https://doi.org/10.1056/EVIDoa2200031>

All Articles in professional peer-reviewed journals

1. **Hu JC**, Palapattu GS, Kattan MW, Scardino PT, Wheeler TM. The association of selected pathological features with prostate cancer in a single-needle biopsy accession. *Hum Pathol*. 1998; 29(12):1536-8.
2. Kattan MW, Fearn PA, Cantor SB, **Hu J**, Cowen ME, Giesler RB, Miles BJ. Telephone interviews vs. workstation sessions for acquiring quality of life data. *Proc AMIA Symp*. 1999: pp. 296-300.
3. Nasu Y, Bangma CH, Hull GW, Lee HM, **Hu J**, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. *Gene Ther*. 1999;6(3):338-49.
4. Carbone JM, Kavalier E, **Hu JC**, Raz S. Pubovaginal sling using cadaveric fascia and bone anchors: disappointing early results. *J Urol*. 2001;165(5):1605-11.
5. **Hu JC**, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical

- prostatectomy outcomes. *J Clin Oncol.* 2003;21(3):401-5.
6. **Hu JC**, Gold KF, Pashos CL, Mehta SS, Litwin MS. Temporal trends in radical prostatectomy complications from 1991 to 1998. *J Urol.* 2003;169(4):1443-8.
 7. Perry KT, Freedland SJ, **Hu JC**, Phelan MW, Kristo B, Gritsch AH, Rajfer J, Schulam PG. Quality of life, pain and return to normal activities following laparoscopic donor nephrectomy versus open mini-incision donor nephrectomy. *J Urol.* 2003;169(6):2018-21.
 8. Perry KT, **Hu JC**, Raman S, Kristo B, Phelan MW, Schulam PG. Natural history of too small to characterize renal lesions observed by computed tomography scan. *J Urol.* 2003;169(4):460-461.
 9. **Hu JC**, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. *J Urol.* 2003;169(6):2279-83.
 10. **Hu JC**, Elkin E, Pasta DJ, Lubeck D, Kattan MW, Carroll P, Litwin MS. Predicting quality after radical prostatectomy: results from CaPSURE. *J Urol.* 2004;171 (2 pt1):703-07.
 11. **Hu JC**, Elkin EP, Pasta DJ, Lubeck, DP, Kattan, MW, Carroll, PR, Litwin, MS. Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. *J Urol.* 2004;171(2):703-708.
 12. **Hu JC**, Nelson RA, Wilson TG, Kawachi MH, Ramin SA, Lau C, Crocitto LE. Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. *J Urol.* 2006;175(2):541-6.
 13. **Hu JC**, Elkin EP, Krupski TL, Gore J, Litwin MS. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor. *Cancer.* 2006;107(2):281-8.
 14. McClellan SN, Hamilton B, Rettenmaier, MA, Lopez K, John CR, **Hu JC**, Goldstein BH. Individual physician experience with laparoscopic supracervical hysterectomy in a single outpatient setting. *Surg Innov.* 2007;14(2):102-6.
 15. Micha JP, Goldstein BH, Graham C, Rettenmaier MA, Brown III JV, **Hu JC**, Markman M. Improved Survival with Single-Agent Paclitaxel Consolidation/Maintenance Therapy in Advanced Ovarian Carcinoma. *Oncology.* 2007;71(1-2):49-53.
 16. **Hu JC**, Link C, McNaughton-Collins M, Barry MJ, McKinlay J. The Association of Abuse and Symptoms Suggestive of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results from the Boston Area Community Health Survey. *J Gen Intern Med.* 2007;22(11):1532-7.
 17. **Hu JC**, Kwan L, Krupski TL, Anger JT, Maliski SL, Connor S, Litwin MS. Determinants of Treatment Regret in Low-Income, Uninsured Men with Prostate Cancer. *Urology.* 2008;72(6):1274-9.
 18. **Hu JC**, Silletti JP, Williams SB. Initial experience with robot-assisted minimally-invasive nephroureterectomy. *J Endourol.* 2008;22(4):699-704.
 19. **Hu JC**, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. *J Clin Oncol.* 2008;26(14):2278-84.
 20. Berry A, Korkes F, **Hu JC**. Landmarks for consistent nerve sparing during robotic-assisted laparoscopic radical prostatectomy. *J Endourol.* 2008;22(8):1565-7.
 21. Berry AM, Korkes F, Ferreira M, **Hu JC**. Robotic urethrovesical anastomosis: combining running and interrupted sutures. *J Endourol.* 2008;22(9):2127-9.
 22. Prasad SM, Keating NL, Wang Q, Pashos CL, Lipsitz S, Richie JP, **Hu JC**. Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy. *Urology.* 2008;72(3):647-52
 23. **Hu JC**, Hevelone ND, Ferreira MD, Lipsitz SR, Choueiri TK, Sanda MG, Earle CC. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. *J Urol.*

- 2008;180(5):1969-74.
24. Micha JP, Rettenmaier MA, Clark M, **Hu JC**, Chang M, Brown JV, Goldstein BH. Successful management of acute renal failure with a vaginal pessary: a case report. *Gynecological Surgery*. 2008;5(1):49-51.
 25. Prasad MM, Hevelone N, Earle CC, Sanda MG, Prasad SM, **Hu JC**. Utilization of pharmacotherapy for erectile dysfunction following surgery for prostate cancer. *J Urol*. 2008;179(4):144.
 26. Prasad SM, Ferreria M, Berry AM, Lipsitz SR, Richie JP, Gawande AA, **Hu JC**. Surgical apgar outcome score: perioperative risk assessment for radical cystectomy. *J Urol*. 2009;181(3):1046-52
 27. Choueiri TK, Xie W, D'Amico AV, Ross RW, **Hu JC**, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. *Cancer*. 2009;115(5):981-7.
 28. Freire MP, Weinberg AC, Lei Y, Soukup JR, Lipsitz SR, Prasad SM, Korke F, Lin T, **Hu JC**. Anatomic Bladder Neck Preservation During Robotic-Assisted Laparoscopic Radical Prostatectomy: Description of Technique and Outcomes. *Eur Urol*. 2009; 56(6): 972-80.
 29. **Hu JC**, Gu X, Lipsitz SR, Barry MJ, D'Amico AV, Weinberg AC, Keating NL. Comparative effectiveness of minimally invasive vs open radical prostatectomy. *JAMA*. 2009;302(14):1557-64.
 30. Hall SA, Link C, **Hu JC**, Eggers P, McKinlay JB. Drug treatment of urologic symptoms: estimating the magnitude of unmet need in a community-based sample. *BJU Int*. 2009;104(11):1680-8.
 31. Rettenmaier CR, Abaid LN, **Hu JC**, Brown JV 3rd, Micha JP, Goldstein BH. Delayed staple erosion into the bladder after removal of a benign ovarian mass. *J Minim Invasive Gynecol*. 2009 Jul-Aug;16(4):491-2.
 32. Ganz M, Smalarz A, Krupski TL, Anger JT, **Hu J**, Kim U, Pashos CL. Economic costs of overactive bladder in the U.S. *Urology*. 2010;75(3):526-32, 532.
 33. Prasad MP, Prasad SM, Hevelone ND, Gu X, Weinberg AC, Lipsitz SR, Palapattu GS, **Hu JC**. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer. *J Sex Medicine*. 2010 Mar;7(3):1062-73.
 34. Hong YM, **Hu JC**, Paciorek AT, Knight SJ, Carroll PR. Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: Results from CaPSURE. *Urol Oncol*. 2010 May-Jun;28(3):268-73.
 35. Ganz ML, Smalarz AM, Krupski TL, Anger JT, **Hu JC**, Wittrup-Jensen KU, Pashos CL. Economic costs of overactive bladder in the United States. *Urology*. 2010;75(3):526-532.
 36. Aho DA, Hoffman KE, **Hu JC**, Choueiri TK, D'Amico AV, Nguyen PL. Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence? Implications for a Risk-adapted Follow-up Strategy. *Urology*. 2010 Nov;76(5):1201-5.
 37. Williams SB, Chen MH, D'Amico AV, Weinberg AC, Kacker R, Hirsch MS, Richie JP, **Hu JC**: Radical Retropubic Prostatectomy and Robotic-assisted Laparoscopic Prostatectomy: Likelihood of Positive Surgical Margins. *Urology*. 2010 Nov;76(5):1097-101.
 38. Williams SB, Alemozaffar M, Lei Y, Hevelone N, Lipsitz SR, Plaster BA, **Hu JC**. Randomized Controlled Trial of Barbed Polyglyconate Versus Polyglactin Suture for Robot-Assisted Laparoscopic Prostatectomy Anastomosis: Technique and Outcomes. *Eur Urol*. 2010 Dec;58(6):875-81.

39. Freire MP, Choi WW, Lei Y, Carvas, F, **Hu JC**. Overcoming the learning curve for robotic-assisted laparoscopic radical prostatectomy. *Urology Clinics*. 2010;37(1):37-47.
40. Prasad SM, Gu, X, Lavelle R, Lipsitz SR, **Hu JC**. Comparative Effectiveness of Perineal versus Retropubic and Minimally Invasive Radical Prostatectomy. *J Urol*. 2011 Jan;185(1):111-5.
41. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, **Hu JC**, Kuban DA, D'Amico AV. Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials. *J Urol*. 2011 Jan;185(1):116-20.
42. **Hu JC**, Prasad SM, Gu X, Williams SB, Lipsitz SR, Nguyen PL, Choueiri TK, Choi WW, and D'Amico AV. Determinants of Performing Radical Prostatectomy Pelvic Lymph Node Dissection and the Number of Lymph Nodes Removed. *Urology*. 2011 Feb;77(2):402-6.
43. Lei Y, Alemozaffar M, Williams SB, Hevelone N, Lipsitz SR, Plaster BA, Amarasekera CA, Ulmer WD, Huang AC, Kowalczyk KJ, **Hu JC**. Athermal Division and Selective Suture Ligation of the Dorsal Vein Complex During Robot Assisted Laparoscopic Radical Prostatectomy: Technique and Outcomes. *Eur Urol*. 2011 Feb;59(2):235-43.
44. Choi WW, Freire MP, Soukup JR, Yin L, Lipsitz SR, Carvas F, Williams SB, **Hu JC**. Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy. *World J Urol*. 2011 Feb;29(1):21-7.
45. Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, **Hu JC**, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men with Small Prostate Size. *Int J Radiat Oncol Biol Phys*. 2011 Apr 1;79(5):1318-22.
46. Huang AC, Kowalczyk KJ, Hevelone ND, Lipsitz SR, Yu HY, Plaster BA, Amarasekara CA, Ulmer WD, Lei Y, Williams SB, **Hu JC**. The impact of prostate size, median lobe, and prior benign prostatic hyperplasia intervention on robot-assisted laparoscopic prostatectomy: technique and outcomes. *Eur Urol*. 2011 Apr;59(4):595-603.
47. Nguyen PL, Je Y, Schutz F, Hoffman KE, **Hu JC**, Parekh A, Beckman JA, Choueiri TK. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *JAMA*. 2011;306(21):2359-2366.
48. Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, **Hu JC**. Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. *J Clin Oncol*. 2011 Apr 20;29(12):1517-24.
49. Choi WW, Williams SB, Gu X, Lipsitz SR, Nguyen PL, **Hu JC**. Overuse of Imaging for staging low risk prostate cancer. 2011 *J Urol*. May;185(5):1645-9.
50. Williams SB, Gu X, Lipsitz SR, D'Amico AV, Weinberg A, **Hu JC**. Population-Based Determinants of Radical Prostatectomy Surgical Margin Positivity. *BJU Int*. 2011 Jun;107(11):1734-40.
51. Williams SB, Prasad SM, Weinberg AC, Shelton JB, Hevelone ND, Lipsitz SR, **Hu JC**. Trends in the Care of Radical Prostatectomy in the United States from 2003-2006. *BJU Int*. 2011 Jul;108(1):49-55.
52. Choueiri TK, Schutz FA, Hevelone ND, Nguyen PL, Lipsitz SR, Williams SB, Silverman SG, **Hu JC**. Thermal ablation vs. surgery for localized kidney cancer: a surveillance, epidemiology, and end results (SEER) database analysis. *Urology*. 2011 Jul;78(1):93-8.
53. Kowalczyk KJ, Huang AC, Hevelone ND, Lipsitz SR, Yu H, Ulmer WD, Kaplan JR, Patel S, Nguyen PL, **Hu JC**. Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. *Eur Urol*. 2011 Sep;60(3):536-47.

54. Kowalczyk KJ, Weinburg AC, Gu X, Yu H, Lipsitz SR, Williams SB, **Hu JC**. Comparison of outpatient narcotic prescribing patterns after minimally invasive vs. retropubic and perineal radical prostatectomy. *J Urol*. 2011 Nov;186(5):1843-8.
55. Williams SB, Gu X, Lipsitz SR, Nguyen PL, Choueiri TK, **Hu JC**. Utilization and Expense of Adjuvant Cancer Therapies Following Radical Prostatectomy. *Cancer*. 2011 Nov 1;117(21):4846-54.
56. **Hu JC**, Yu HY, Kowalczyk KJ. Challenges of interpreting and improving radical prostatectomy outcomes: technique, technology, training, and tactical reporting. *European Urology*. 2011;59(6):1073-1074.
57. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, **Hu JC**, Parekh AN, Beckman JA, Choueiri TK. Meta-analysis of the impact of androgen deprivation therapy on cardiovascular death in patients with prostate cancer. *JAMA*. 2011 Dec 7;306(21):2359-66.
58. Prasad SM, Gu X, Lipsitz SR, Nguyen PL, and **Hu JC**. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. *Cancer*. 2012 Mar 1;118(5):1260-7.
59. Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, **Hu JC**, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. *Int J Radiat Oncol Biol Phys*. 2012 Mar 15;82(4):1411-6.
60. Kowalczyk KJ, Levy JM, Caplan CF, Lipsitz SR, Yu H, **Hu JC**. Temporal National Trends of Minimally Invasive and Retropubic Radical Prostatectomy Outcomes from 2003 to 2007: Results from the 100% Medicare Sample. *Eur Urol*. 2012 Apr;61(4):803-9.
61. Yu H, Hevelone ND, Lipsitz SR, Kowalczyk KJ, **Hu JC**. Use, costs and comparative effectiveness of robotic-assisted, laparoscopic, and open urologic surgery. *J Urol*. 2012. Apr;187(4):1392-8.
62. Prasad SM, Drazer MW, Huo D, **Hu JC**, Eggen SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. *JAMA*. 2012 Apr 25;307(16):1692-4.
63. Kowalczyk KJ, Alemozaffar M, Hevelone ND, Ulmer WD, Plaster BA, Lipsitz SR, Yu H, **Hu JC**. Partial Clamping of the Renal Artery During Robotic-Assisted Laparoscopic Partial Nephrectomy: Technique and Initial Outcomes. *J Endourol*. 2012 May;26(5):496-73
64. Yu H, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, **Hu JC**. Hospital volume, utilization, costs and outcomes of robotic-assisted laparoscopic radical prostatectomy. *J Urol*. 2012 May;187(5):1632-7.
65. Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, Choueiri TK, **Hu JC**, Kantoff PW, D'Amico AV, Nguyen PL. Post-treatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. *J Urol*. 2012 Jun;187(6):2068-73.
66. **Hu JC**, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen deprivation therapy for non-metastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. *Eur Urol*. 2012 Jun;61(6):1119-28.
67. Alemozaffar M, Duclos A, Hevelone ND, Lipsitz SR, Borza T, Yu HY, Kowalczyk KJ, **Hu JC**. Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. *Eur Urol*. 2012 Jun;61(6):1222-8.

68. Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, Choueiri TK, Kibel AS, **Hu JC**. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. *Eur Urol*. 2012 Jun;61(6):1239-44.
69. Nguyen PL, Chen MH, Hoffman KE, Chen RC, **Hu JC**, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. *BJU Int*. 2012 Jul;11(2):201-5.
70. Williams SB, Lei Y, Nguyen PL, Gu X, Lipsitz SR, Yu H, Kowalczyk KJ, **Hu JC**. Comparative effectiveness of cryotherapy vs. brachytherapy for localised prostate cancer. *BJU Int*. 2012 Jul;110(2 Pt 2):E92-8.
71. Choi WW, Gu X, Lipsitz SR, D'Amico AV, **Hu JC**. The Effect of Minimally Invasive and Open Radical Prostatectomy Surgeon Volume. *Urol Oncol*. 2012 Sep;30(5):569-76.
72. Ulmer WD, Prasad SM, Kowalczyk KJ, Gu X, Dodgion C, Lipsitz S, Palapattu GS, Choueiri TK, **Hu JC**. Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. *J Urol*. 2012 Sep;188(3):775-80.
73. Friedlander DF, Alemozaffar M, Hevelone ND, Lipsitz SR, **Hu JC**. Stepwise description and outcomes of bladder neck sparing during robot-assisted laparoscopic radical prostatectomy. *J Urol*. 2012 Nov;188(5):1754-60.
74. Williams SB, Amarasekera CA, Gu X, Lipsitz SR, Nguyen PL, Hevelone ND, Kowalczyk KJ, **Hu JC**. Influence of surgeon and hospital volume on radical prostatectomy costs. *J Urol*. 2012 Dec;188(6):2198-204.
75. Carter S, Konijeti R, **Hu J**. Selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy. *J Endourol* 2012 Dec;26(12):1576-7.
76. Parekh A, Chen MH, Hoffman KE, Choueiri TK, **Hu JC**, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penis size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation therapy, or radiotherapy alone. *Urology*. 2013 Jan;81(1):130-5.
77. **Hu JC**, Khanna A, Gu X, Nguyen PL, Lipsitz S, Palapattu GS. Certificate of Need Programs, Intensity Modulated Radiation Therapy Use and the Cost of Prostate Cancer Care. *J Urol*. 2013 Jan;189(1):75-9.
78. Parekh A, Chen MH, Hoffman KE, Choueiri TK, **Hu JC**, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. *Urology*. 2013 Jan;81(1):130-4.
79. Sammon JD, Karakiewicz PI, Sun M, Sukumar S, Ravi P, Ghani KR, Bianchi M, Peabody JO, Shariat SF, Perrotte P, **Hu JC**, Menon M, Trinh QD. Robot-assisted vs. Open radical prostatectomy: The differential effect of regionalization, procedure volume and operative approach. *J Urol* 2013 Apr;189(4):1289-94.
80. Kaplan JR, Kowalczyk KJ, Borza T, Gu X, Lipsitz SR, Nguyen PL, Friedlander DF, Trinh Q-D, **Hu JC**. Patterns of care and outcomes of radiotherapy for lymph node positivity following radical prostatectomy. *BJU Int*. 2013 Jun;111(8):1208-14.
81. Kowalczyk KJ, Huang AC, Hevelone ND, Lipsitz SR, Yu HY, Lynch JH, **Hu JC**. Effect of minimizing tension during robotic-assisted laparoscopic radical prostatectomy on urinary function recovery. *World J Urol*. 2013 Jun;31(3):515-21.
82. Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, Shariat SF, Larouche A, Tian Z, Kim SP, Kowalczyk KJ, **Hu JC**, Menon M, Karakiewicz PI, Trinh QD, Sun M. Health care-

- associated infections after major cancer surgery: Temporal trends, patterns of care, and effect on mortality. *Cancer*. 2013 Jun 15;119(12):2317-24.
83. Sukumar S, Roghmann F, Trinh VQ, Sammon JD, Gervais MK, Tan HJ, Ravi P, Kim SP, **Hu JC**, Karakiewicz PI, Noldus J, Sun M, Menon M, Trinh QD. National trends in hospital-acquired preventable adverse events after major cancer surgery in the USA. *BMJ Open*. 2013 Jun 26;3(6).
 84. Trinh VQ, Trinh QD, Tian Z, **Hu JC**, Shariat SF, Perrotte P, Karakiewicz PI, Sun M. In-hospital mortality and failure-to-rescue rates after radical cystectomy. *BJU Int*. 2013 Jul;112(2):E20-7.
 85. Kowalczyk KJ, Choueiri TK, Hevelone ND, Trinh QD, Lipsitz SR, Nguyen PL, Lynch JH, **Hu JC**. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. *BJU Int*. 2013 Aug;112(4):E273-80.
 86. Kaplan AL, **Hu JC**. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. *Urology*. 2013 Aug;82(2):321-6.
 87. Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, **Hu JC**, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. *Brachytherapy*. 2013 Sep-Oct;12(5):415-21.
 88. Kowalczyk KJ, Harbin AC, Choueiri TK, Hevelone ND, Lipsitz SR, Trinh QD, Tina Shih YC, **Hu JC**. Utilization of surveillance imaging following treatment of small renal masses. *J Urol*. 2013 Nov;190(5):1680-5.
 89. Prasad SM, Gu X, Kowalczyk KJ, Lipsitz SR, Nguyen PL, **Hu JC**. Morbidity and costs of salvage vs. primary radical prostatectomy in older men. *Urol Oncol*. 2013 Nov;31(8):1477-82. Doi: 10.1016/j.urolonc.2012.04.004.
 90. Aizer AA, Chen M-H, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, **Hu JC**, and Nguyen PL. Marital Status and Survival in Patients With Cancer. *J Clin Oncol*. 2013 Nov 1;31(31):3869-76.
 91. Shih Y-CT, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin J, **Hu JC**, Schrag D, Temel J, Schnipper L. Delivering High-Quality and Affordable Care throughout the Cancer Care Continuum. *J Clin Oncol*. 2013 Nov 10;31(32):4151-7.
 92. Kowalczyk KJ, Huang AC, Williams SB, Yu HY, **Hu JC**. Robotic-assisted laparoscopic radical prostatectomy after aborted retropubic radical prostatectomy. *Journal of Robotic Surgery*. 2013;7(3):301-304.
 93. Yu HY, Friedlander DF, Patel S, **Hu JC**. The current status of robotic oncologic surgery. *Cancer*. 2013;63(1):45-56.
 94. Kowalczyk KJ, Gu X, Nguyen PL, Lipsitz SR, Trinh QD, Lynch JH, Collins SP, **Hu JC**. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. *Urol Oncol*. 2013 Dec 6. Pii: S1078-1439(13)00347-5.
 95. Trinh QD, Sun M, Kim SP, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, Shariat SF, **Hu JC**, Menon M, Karakiewicz PI. The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. *Urol Oncol*. 2014 Jan;32(1):29.e13-20.
 96. Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais M-K, Shariat SF, Tian Z, Kim SP, Kowalczyk KJ, **Hu JC**, Menon M, Trinh Q-D. Venous thromboembolism after major cancer surgery temporal trends and patterns of care. *JAMA Surg*. 2014 Jan;149(1):43-9.

97. Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, **Hu JC**, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Abdollah F. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. *BJU Int.* 2014 Jan; 114(6b):E62-E69. Doi: 10.1111/bju.12645.
98. Gandaglia G, Sun M, **Hu JC**, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Euro Urol.* 2014 Jan 28. Pii: S0302-2838(14)00095-5.
99. **Hu JC**, Liu C-H, Treat EG, Ernest A, Veale J, Carter SC, Huang K-H, Blumberg JM, Schulam PG, Gritsch HA. Determinants of Laparoscopic Donor Nephrectomy Outcomes. *Euro Urol.* 2014 Mar;65(3):659-64.
100. Friedlander DF, Gu X, Lipsitz SR, **Hu JC**. Population-Based Comparative Effectiveness of Salvage Radical Prostatectomy Versus Cryotherapy. *Urol.* 2014 Mar;83(3):653-7.
101. Kaplan A, Nguyen PL, Trinh Q-D, Shih Y-CT, Marks L, Sun M, **Hu JC**. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. *J Sex Medicine.* 2014 Apr;11(4):1063-70.
102. Bakan J, Chen B, Medeiros-Nancarrow C, **Hu JC**, Kantoff PW, Recklitis CJ. Effects of a gift certificate incentive and specialized delivery on prostate cancer survivors' response rate to a mailed survey: A randomized-controlled trial. *J Geriatr Oncol.* 2014 Apr;5(2):127-32.
103. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, Shariat SF, Kim SP, Kowalczyk KJ, **Hu JC**, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg.* 2014 Apr;57(2):82-8.
104. Gandaglia G, Sammon JD, Chang SL, Choueiri TK, **Hu JC**, Karakiewicz PI, Kibel AS, Kim SP, Konijeti R, Montorsi F, Nguyen PL, Sukumar S, Menon M, Sun M, and Trinh Q-D. Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the "Post-Dissemination" Era. *J Clin Oncol.* 2014 May 10;32(14):1419-26.
105. Carter SC, Lipsitz S, Shih YC, Nguyen PL, Trinh QD, **Hu JC**. Population-based determinants of radical prostatectomy operative time. *BJU Int.* 2014 May;113(5b):E112-8.
106. Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Trinh QD, **Hu JC**, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. *Cancer.* 2014 May 15;120(10):1532-9.
107. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, **Hu JC**, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. *J Geriatr Oncol.* 2014 May 23. Pii: S1879-4068(14)00069-1.
108. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, **Hu JC**, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. *Urol Oncol.* 2014 May 17. Pii: S1078-1439(14)00156-2.
109. Huang KH, Kaplan A, Carter SC, Lipsitz S, **Hu JC**. The impact of radical prostatectomy operative time on outcomes and costs. *Urol.* 2014 Jun;83(6):1265-71.
110. Gandaglia G, Trinh QD, **Hu JC**, Schiffmann J, Becker A, Roghmann F, Popa I, Tian Z, Perrotte P, Montorsi F. The impact of robot-assisted radical prostatectomy on the use and extent

of pelvic lymph node dissection in the “post-dissemination” period. *Eur Urol*. 2014;40(9):1080-1086.

111. **Hu JC**, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, Trinh QD, Sun M, Nguyen PL, Lipsitz SR. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. *Urol Oncol*. 2014 Jul 10. Pii: S1078-1439(14)00209-9.
112. Aizer AA, Falit B, Mendu ML, Chen MH, Choueiri TK, Hoffman KE, **Hu JC**, Martin NE, Trinh QD, Alexander B, Nguyen PL. Cancer-specific outcomes among young adults without health insurance. *J Clin Oncol*. 2014 Jul 1;32(19):2025-30.
113. Aizer AA, Chen MH, Parekh A, Choueiri TK, Hoffman KE, Kim SP, Martin NE, **Hu JC**, Trinh QD, Nguyen PL. Refusal of curative radiation therapy and surgery among patients with cancer. *Int J Radiat Oncol Biol Phys*. 2014 Jul 15;89(4):756-64.
114. Prasad S MD, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA and **Hu JC**. The effect of depression on the diagnosis, treatment and mortality of men with clinically localized prostate cancer. *J Clin. Oncol*. 2014 Aug 10;32(23):2471-8.
115. **Hu JC**, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, Marks LS. Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply? *J Urol*. 2014 Aug;192(2):385-90.
116. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, **Hu JC**, Sweeney CJ, Beard CJ, D’Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. *Urology*. 2014 Aug;84(2):386-92.
117. Williams SB, **Hu JC**. Predicting biochemical recurrence following salvage radiotherapy: applying lessons learned from primary radiotherapy. *Eur Urol*. 2014 Sep;66(3):487-8.
118. **Hu JC**, Treat E, Filson CP, McLaren I, Xiong S, Stepanian S, Hafez KS, Weizer AZ, Porter J. Technique and Outcomes of Robotic-Assisted Retroperitoneoscopic Partial Nephrectomy: a Multi-Center Study. *Eur Urol*. 2014 Sep;66(3):542-9.
119. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, **Hu JC**, Sweeney CJ, Beard CJ, D’Amico AV, Martin NE, Trinh QD, Nguyen PL. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. *Prostate Cancer Prostatic Dis*. 2014 Sep;17(3):273-9.
120. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, **Hu JC**, Hoffman KE, Sweeney CJ, Beard CJ, D’Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. *Clin Genitourin Cancer*. 2014 Oct;12(5):e189-95.
121. Laviana AA, **Hu JC**. Understanding Long-term Urinary Adverse Events After Treatment of Localized Prostate Cancer: A Key Tool in Informed Decision-making. *Eur Urol*. 2014 Oct 1. Pii: S0302-2838(14)00966
122. Sun M, Sammon JD, Becker A, Roghmann F, Tian Z, Kim SP, Larouche A, Abdollah F, **Hu JC**, Karakiewicz PI. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. *BJU Int*. 2014;113(2):200-208.
123. Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE, **Hu JC**, Beard CJ, D’Amico AV. Incidence and determinants of 1-month mortality after cancer-directed surgery. *Annals of Oncology*. 2014;26(2):399-406.
124. **Hu JC**, Gandaglia G, Nguyen PL, Trinh Q-D, Shih Y-CT, Abdollah F, Chamie K, Wright JL, Karakiewicz PI, Ganz PA, Sun M. Comparative effectiveness of robotic-assisted versus open radical prostatectomy cancer control. *Euro Urol*. 2014 Oct;66(4):666-72.

125. Recklitis CJ, Zhou ES, Zwemer EK, **Hu JC**, Kantoff PW. Suicidal ideation in prostate cancer survivors: Understanding the role of physical and psychological health outcomes. *Cancer*. 2014 Nov 1;120(21):3393-400. Doi: 10.1002/cncr.28880.
126. Kaplan AL, Lenis AT, Shah A, Rajfer JR, **Hu JC**. Testosterone replacement therapy in men with prostate cancer: A time-varying analysis. *J Sex Med*. 2014 Dec;12(2):374-380. Doi:10.1111/jsm.12768.
127. Gandaglia G, Abdollah F, **Hu J**, Kim S, Briganti A, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F. Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments. *Journal of endourology*. 2014;28(7):784-791.
128. **Hu JC**, Gandaglia G, Karakiewicz PI, Nguyen PL, Trinh QD, Shih YA, Abdollah F, Chamie K, Wright JL, Ganz PA. Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. *Eur Urol*. 2014;66(4):666-672.
129. Treat EG, Schulam PG, Gritsch HA, Liu C-H, Xiong S, Huang K-H, Passos F, **Hu JC**. Evolution of Laparoscopic Donor Nephrectomy: a Single-Center Experience with over 1300 cases. *Urol*. 2015 Jan;85(1):107-12. Doi: 10.1016/j.urology.2014.09.027.
130. Carter SC, Chiang A, Shah G, Kwan L, Montgomery JS, Karam A, Tarnay C, Guru KA, **Hu JC**. Video-based peer feedback through social networking for robotic surgery simulation: a 33 multicentre randomized controlled trial. *Annals of Surgery*. 2015;261(5):870-875.
131. Geynisman DM, **Hu JC**, Liu L, Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. *Clinical Genitourinary Cancer*. 2015;13(2):e93-e100.
132. Sammon JD, Abdollah F, Reznor G, Pucheril D, Choueiri TK, **Hu JC**, Kim SP, Schmid M, Sood A, Sun M. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. *Eur Urol*. 2015;68(1):32-39.
133. Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH, **Hu JC**, Kibel AS, Nguyen PL, Peabody JO. Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. *Urology*. 2015;85(2):343-350.
134. Sukumar S, Ravi P, Sood A, Gervais MK, **Hu JC**, Kim SP, Menon M, Roghmann F, Sammon JD, Sun M. Racial disparities in operative outcomes after major cancer surgery in the United States. *World Journal of Urology*. 2015;39(3):634-643.
135. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, **Hu JC**, Sweeney CJ, Beard CJ, D'Amico AV. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? *The American Journal of Medicine*. 2015;128(6):609-616.
136. Raza SJ, Field E, Jay C, Eun D, Fumo M, **Hu JC**, Lee D, Mehboob Z, Nyquist J, Peabody JO. Surgical competency for urethrovesical anastomosis during robot-assisted radical prostatectomy: development and validation of the robotic anastomosis competency evaluation. *Urology*. 2015;85(1):27-32.
137. Lipsitz SR, Fitzmaurice GM, Sinha D, Hevelone N, Giovannucci E, **Hu JC**. Testing for independence in JxK contingency tables with complex sample survey data. *Biometrics*. 2015 Mar 11.
138. Zhou ES, **Hu JC**, Kantoff PW, Recklitis CJ. Identifying suicidal symptoms in prostate cancer survivors using brief self-report. *J Cancer Surviv*. 2015 Mar;9(1):59-67. Doi: 10.1007-s11764-014-0385-z.
139. Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efsthathiou JA, Hyatt AS, Graham PL, Trinh QD, **Hu JC**. Cost implications and complications of overtreatment of low-risk

- prostate cancer in the United States. *Journal of the National Comprehensive Cancer Network*. 2015;13(1):61-68.
140. Kaplan AL, Ehrlich RM, Marks LS, Walsh PC, Bloom DA, **Hu JC**. Joseph J. Kaufman: renaissance man. *Urology*. 2015 Mar;85(3):487-90.
 141. Chamie K, Williams SB, **Hu JC**. Population-Based Assessment of Determining Treatments for Prostate Cancer. *JAMA Oncol*. 2015 Apr;1(1):60-7. Doi: 10.1001/jamaoncol.2014.192.
 142. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, **Hu JC**, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? *BJU Int*. 2015 Jul 24.
 143. Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezoslosky MD, Choueiri TK, Hoffman KE, **Hu JC**, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. *Urol Oncol*. 2015 Jul;33(7):330.e19-25. Doi: 10.1016/j.urolonc.2015.03.010.
 144. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, **Hu JC**, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy with Excess Cardiac-Specific Mortality in Men with Prostate Cancer. *BJU Int*. 2015 Sep;116(3):358-65. Doi: 10.1111/bju.12905.
 145. Abaza R, Shabsigh A, Castle E, Allaf M, **Hu JC**, Rogers C, Menon M, Aron M, Sundaram CP, Eun D. Multi-Institutional Experience with Robotic Nephrectomy with Inferior Vena Cava Tumor Thrombectomy. *J Urol*. 2015 Nov 19. Pii: S0022-5347(15)05245-3. Doi: 10.1016/j.juro.2015.09.094.
 146. Wang LC, Al Hussein Al Awamlh B, **Hu JC**, Laudano MA, Davison WL, Schulster ML, Zhao F, Chughtai B, Lee RK. Trends in Mesh Use for Pelvic Organ Prolapse Repair From the Medicare Database. *Urology*. 2015 Nov;86(5):885-91.
 147. Chamie K, Williams SB, Hershman DL, Wright JD, Nguyen PL, **Hu JC**. Population-based assessment of determining predictors for quality of prostate cancer surveillance. *Cancer*. 2015 Dec 1;121(23):4150-7.
 148. Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, Sun M, Aizer AA, Choueiri TK, **Hu JC**, Kim SP, Kibel AS, Nguyen PL, Menon M, Trinh QD. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥ 66 years. *Eur J Surg Oncol*. 2015 Nov;41(11):1529-39.
 149. Accordino MK, Wright JD, Vasan S, Neugut AI, Tergas A, **Hu JC**, Hershman DL, Accordino MK, Wright JD, Vasan S, Neugut AI, Tergas A, Hershman DL. ReCAP: Serum Tumor Marker Use in Patients With Advanced Solid Tumors. *J Oncol Pract*. 2016 Jan;12(1):65-6.
 150. Tan H-J, Chuang RJ, Shirk JD, Laviana AA, **Hu JC**. Health insurance status and disparities in kidney cancer care. *Urology Practice*. 2016 Jan;3(1):18-24.
 151. Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y, **Hu JC**, Ananth CV, Neugut AI, Hershman DL. Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. *Obstet Gynecol*. 2016 Jan;127(1):101-8.
 152. Wright JD, Huang Y, Burke WM, Tergas AI, Hou JY, **Hu JC**, Neugut AI, Ananth CV, Hershman DL. Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer. *Obstet Gynecol*. 2016 Jan;127(1):109-18
 153. Laviana AA, Ilg AM, Veruttipong D, Tan HJ, Burke MA, Niedzwiecki DR, Kupelian PA, King CR, Steinberg ML, Kundavaram CR, Kamrava M, Kaplan AL, Moriarity AK, Hsu W, Margolis DJ, Saigal CS, **Hu JC**. Utilizing time-driven activity-based costing to understand the short-

and long-term costs of treating localized, low-risk prostate cancer. *Cancer*. 2016 Feb 1;122(3):447-55.

154. Wright JD, Burke WM, Tergas AI, Hou JY, Huang Y, **Hu JC**, Hillyer GC, Ananth CV, Neugut AI, Hershman DL. Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. *J Clin Oncol*. 2016 Feb 1. Pii: JCO653212.
155. Margolis B, Tergas AI, Chen L, Hou JY, Burke WM, **Hu JC**, Ananth CV, Neugut AI, Hershman DL, Wright JD. Natural history and outcome of neuroendocrine carcinoma of the cervix. *Gynecol Oncol*. 2016 Feb 9. Pii: S0090-8258(16)30034-8. Doi: 10.1016/j.ygyno.2016.02.008.
156. Wright JD, Margolis B, Hou JY, Burke WM, Tergas AI, Huang Y, **Hu JC**, Ananth CV, Neugut AI, Hershman DL. Overuse of External Beam Radiotherapy for Stage I Endometrial Cancer. *Am J Obstet Gynecol*. 2016 Feb 11. Pii: S0002-9378(16)00291-X. doi: 10.1016/j.ajog.2016.02.007.
157. Wright JD, Tergas AI, Hou JY, Burke WM, Chen L, **Hu JC**, Neugut AI, Ananth CV, Hershman DL. Effect of Regional Hospital Competition and Hospital Financial Status on the Use of Robotic-Assisted Surgery. *JAMA Surg*. 2016 Feb 17. Doi: 10.1001/jamasurg.2015.5508.
158. Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, **Hu JC**, Ananth CV, Neugut AI, Hershman DL, Wright JD. Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. *Gynecol Oncol*. 2016 Mar;140(3):387-93
159. Wright JD, Tergas AI, Hou JY, Burke WM, Huang Y, **Hu JC**, Hillyer GC, Ananth CV, Neugut AI, Hershman DL. Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors. *Obstet Gynecol*. 2016 Mar;127(3):449-58.
160. Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. *Eur Urol Focus*. 2017 Apr;3(2-3):258-264. Doi: 10.1016/j.euf.2016.04.008.
161. Laviana AA, Kundavaram CR, Tan H-J, Burke MA, Niedzwiecki D, Lee RK, **Hu JC**. Determining the true costs of treating small renal masses using time driven, activity based costing. *Urology Practice*. 2016 May;3(3):180-186.
162. Shoag JE, Mittal S, **Hu JC**. Reevaluating PSA Testing Rates in the PLCO Trial. *N Engl J Med*. 2016 May 5;374(18):1795-6. Doi: 10.1056/NEJMc1515131.
163. Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezoslosky MD, Choueiri TK, Hoffman KE, **Hu JC**, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. *J Clin Oncol*. 2016 Jun 1. Doi: 10.1200/JCO.2015.64.1969
164. Halpern JA, Lee UJ, Wolff EM, Mittal S, Shoag JE, Lightner DJ, Kim S, **Hu JC**, Chughtai B, Lee RK. Women in Urology Residency, 1978-2013: A Critical Look at Gender Representation in Our Specialty. *Urology*. 2016 Jun. doi: 10.1016/j.urology.2015.12.092.
165. Wright JD, Chen L, Jorge S, Burke WM, Tergas AI, Hou JY, **Hu JC**, Neugut AI, Ananth CV, Hershman DL. Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. *Gynecol Oncol*. 2016 Jun. doi: 10.1016/j.ygyno.2016.03.023.
166. Chatterjee S, Chen L, Tergas AI, Burke WM, Hou JY, **Hu JC**, Ananth CV, Neugut AI, Hershman DL, Wright JD. Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer. *Obstet Gynecol*. 2016 Jun;127(6):992-1002. Doi:10.1097/AOG.0000000000001404.

167. Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, **Hu JC**, Ananth CV, Neugut AI, Hershman DL. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. *Obstet Gynecol.* 2016 Jun;127(6):985-91. Doi:10.1097/AOG.0000000000001436.
168. **Hu JC**, Laviana A, Sedrakyan A. High-Intensity Focused Ultrasound for Prostate Cancer: Novelty or Innovation? *JAMA.* 2016 Jun 28;315(24):2659-60. Doi:10.1001/jama.2016.5002.
169. **Hu JC**, Chughtai B, O'Malley P, Halpern JA, Mao J, Scherr DS, Hershman DL, Wright JD, Sedrakyan A. Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study. *Eur Urol.* 2016 Jul;70(1):195-202. Doi: 10.1016/j.eururo.2016.03.028.
170. Shoag J, Mittal S, Halpern JA, Scherr D, **Hu JC**, Barbieri CE. Lethal Prostate Cancer in the PLCO Cancer Screening Trial. *Eur Urol.* 2016 Jul;70(1):2-5. Doi:10.1016/j.eururo.2016.01.009.
171. **Hu JC**, Nanus DM, Sedrakyan A. Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States. *Eur Urol.* 2016 Jul 8. Pii:S0302-2838(16)30388-8. Doi:10.1016/j.eururo.2016.06.036.
172. Shoag JE, Schlegel PN, **Hu JC**. Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum. *J Clin Oncol.* 2016 Jul 18. Pii:JCO678938.
173. Zhou ES, Bober SL, Nekhlyudov L, **Hu JC**, Kantoff PW, Recklitis CJ. Physical and emotional health information needs and preferences of long-term prostate cancer survivors. *Patient Educ Couns.* 2016 Jul 14. Pii: S0738-3991(16)30312-3. Doi: 10.1016/j.pec.2016.07.017.
174. Halpern JA, Shoag JE, Hu JC. Editorial Comment. *J Urol.* 2016 Aug;196(2):380-1. Doi:10.1016/j.juro.2016.02.2990.
175. Accordino MK, Wright JD, Vasan S, Neugut AI, Hillyer GC, **Hu JC**, Hershman DL. Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. *J Clin Oncol.* 2016 Aug 20;34(24):2820-6. Doi: 10.1200/JCO.2016.66.6313.
176. Halpern JA, Sedrakyan A, Hsu WC, Mao J, Daskivich TJ, Nguyen PL, Golden EB, Kang J, **Hu JC**. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. *Cancer.* 2016 Aug 15;122(16):2496-504. Doi:10.1002/cncr.30101.
177. Shirk JD, Tan HJ, **Hu JC**, Saigal CS, Litwin MS. Patient experience and quality of urologic cancer surgery in US hospitals. *Cancer.* 2016 Aug 15;122(16):2571-8. Doi: 10.1002/cncr.30081. PubMed PMID: 27254231.
178. Tan HJ, Chamie K, Daskivich TJ, Litwin MS, **Hu JC**. Patient function, long-term survival, and use of surgery in patients with kidney cancer. *Cancer.* 2016 Aug 12. Doi: 10.1002/cncr.30275.
179. Williams SB, Duan Z, Chamie K, Hoffman KE, Smith BD, **Hu JC**, Shah JB, Davis JW, Giordano SH. Risk of hospitalisation after primary treatment for prostate cancer. *BJU Int.* 2016 Aug 25. Doi: 10.1111/bju.13647.
180. Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, Wright JD, Tina Shih YC, Nguyen PL, **Hu JC**. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm. *J Urol.* 2016 Aug 26. Pii: S0022-5347(16)31147-8. Doi: 10.1016/j.juro.2016.08.092.
181. Halpern JA, Al Hussein Al Awamlh B, Mittal S, Shoag JE, **Hu JC**, Lee RK. International Medical Graduate Training in Urology: Are We Missing an Opportunity? *Urology.* 2016 Sep;95:39-46. Doi:10.1016/j.urology.2016.03.063.

182. Yoon L, Clarke Hillyer G, Chen L, **Hu JC**, Neugut AI, Hershman DL, Wright JD. Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. *Cancer Invest.* 2016 Sep 13;34(8):408-14. Doi:10.1080/07357907.2016.1221078.
183. Molina AM, **Hu J**, Nanus DM. Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival? *J Clin Oncol.* 2016 Sep 20;34(27):32356. Doi: 10.1200/JCO.2016.68.4050.
184. Daskivich TJ, Tan HJ, Litwin MS, **Hu JC**. Life Expectancy and Variation in Treatment for Early Stage Kidney Cancer. *J Urol.* 2016 Sep. doi: 10.1016/j.juro.2016.03.133
185. Pereira K, Halpern JA, McClure TD, Lewis NA, Kably I, Bhatia S, **Hu JC**. Role of prostate artery embolization in the management of refractory haematuria of prostatic origin. *BJU Int.* 2016 Sep;118(3):359-65. Doi: 10.1111/bju.13524.
186. Filson CP, Tan HJ, Chamie K, Laviana AA, **Hu JC**. Determinants of radical cystectomy operative time. *Urol Oncol.* 2016 Oct;34(10):431.e17-24. Doi:10.1016/j.urolonc.2016.05.006.
187. Cham S, Chen L, Burke WM, Hou JY, Tergas AI, **Hu JC**, Ananth CV, Neugut AI, Hershman DL, Wright JD. Utilization and Outcomes of Sentinel Lymph Node Biopsy for Vulvar Cancer. *Obstet Gynecol.* 2016 Oct;128(4):754-60. Doi:10.1097/AOG.0000000000001648.
188. **Hu JC**, O'Malley P, Chughtai B, Isaacs A, Mao J, Wright JD, Hershman D, Sedrakyan A. Comparative Effectiveness of Cancer Control and Survival after Robot-Assisted versus Open Radical Prostatectomy. *J Urol.* 2016 Oct 5. Pii:S0022-5347(16)31441-0. Doi:10.1016/j.juro.2016.09.115.
189. Tan HJ, Xiong S, Laviana AA, Chuang RJ, Treat E, Walsh PC, **Hu JC**. Technique and outcomes of bladder neck intussusception during robot-assisted laparoscopic prostatectomy: A parallel comparative trial. *Urol Oncol.* 2016 Oct 12. Pii:S1078-1439(15)00045-9. Doi:10.1016/j.urolonc.2015.01.012.
190. Shoag J, Halpern JA, Lee DJ, Mittal S, Ballman KV, Barbieri CE, **Hu JC**. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. *J Urol.* 2016 Oct. doi:10.1016/j.juro.2016.03.171
191. Shoag JE, Mittal S, **Hu JC**. More on Reevaluating PSA Testing Rates in the PLCO Trial. *N Engl J Med.* 2016 Oct 13;375(15):1500-1501. Doi: 10.1056/NEJMc1607379.
192. Halpern JA, Shoag JE, Artis AS, Ballman KV, Sedrakyan A, Hershman DL, Wright JD, Shih YC, **Hu JC**. National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the United States Preventative Services Task Force Guidelines Against Prostate-Specific Antigen Screening. *JAMA Surg.* 2016 Nov 2. Doi: 10.1001/jamasurg.2016.3987.
193. Halpern JA, Sedrakyan A, Dinerman B, Hsu WC, Mao J, **Hu JC**. Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis. *J Urol.* 2016 Nov 14. Pii: S0022-5347(16)31785-2. Doi: 10.1016/j.juro.2016.11.081.
194. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, **Hu JC**, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? *Cancer.* 2016 Nov 15;122(21):3371-3377. Doi:10.1002/cncr.30205.
195. Hussein AA, Ghani KR, Peabody J, Sarle R, Abaza R, Eun D, **Hu J**, Fumo M, Lane B, Montgomery J, Hinata N, Rooney D, Comstock B, Chan HK, Mane SS, Mohler JL, Wilding G, Miller D, Guru KA, Michigan Urological Surgery Improvement Collaborative And Applied Technology Laboratory for Advanced Surgery Program. Development and Validation of an

- Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation. *J Urol*. 2016 Nov 29. Pii: S0022-5347(16)31879-1. Doi: 10.1016/j.juro.2016.11.100.
196. Golombos DM, Chughtai B, Trinh QD, Mao J, Te A, O'Malley P, Scherr DS, Del Pizzo J, **Hu JC**, Sedrakyan A. Adoption of Technology and Its Impact on Nephrectomy Outcomes, a U.S. Population-Based Analysis (2008-2012). *J Endourol*. 2016 Nov 30. Doi: 10.1089/end.2016.0643.
197. Tan HJ, Daskivich TJ, Shirk JD, Filson CP, Litwin MS, **Hu JC**. Health status and use of partial nephrectomy in older adults with early-stage kidney cancer. *Urol Oncol*. 2016 Dec 7. Pii: S1078-1439(16)30373-8. Doi: 10.1016/j.urolonc.2016.11.007.
198. Tan HJ, Shirk JD, Chamie K, Litwin MS, **Hu JC**. Patient Function and the Value of Surgical Care for Kidney Cancer. *J Urol*. 2016 Dec 13. Pii: S0022-5347(16)31932-2. Doi: 10.1016/j.juro.2016.12.012.
199. Dobbs RW, Magnan BP, Abhyankar N, Hemal AK, Challacombe B, **Hu J**, Dasgupta P, Porpiglia F, Crivellaro S. Cost effectiveness and robot-assisted urologic surgery: does it make dollars and sense? *Minerva Urol Nefrol*. 2016 Dec 22.
200. **Hu JC**, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, Sedrakyan A. Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. *JAMA Oncol*. 2016 Dec 29. Doi: 10.1001/jamaoncol.2016.5465.
201. Cui Z, Wright JD, Accordino MK, Buono D, Neugut AI, **Hu JC**, Hersman DL. Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. *Cancer Invest*. 2016. Doi: 10.3109/07357907.2016.1166232
202. Dinh KT, Gally Reznor VM, Mahal BA, Nezoslosky MD, Choueiri TK, Hoffman KE, **Hu JC**, Sweeney CJ, Trinh QD, Ngyuen PL. Association of androgen deprivation therapy with depression in localized prostate cancer. *Journal of Clinical Oncology*. 2016;34(16):1905.
203. Halpern JA, Mittal S, Shoag JE, Hersman DL, Wright JD, Lee RK, **Hu JC**. Temporal trends and practice patterns in the urology work force between low and high density population areas. *Urology Practice*. 2017 Jan; 4(1):91-95.
204. Bergman J, Laviana AA, Kwan L, Lerman SE, Aronson WJ, Bennett CJ, **Hu JC**. Variations in payment patterns for surgical care in the centers for Medicare and Medicaid Services. *Surgery*. 2017 Feb;161(2):312-319. Doi:10.1016/j.surg.2015.12.028.
205. Wright JD, Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Desai V, **Hu JC**, Ananth CV, Neugut AI, Hersman DL. Utilization of sentinel lymph node biopsy for uterine cancer. *Am J Obstet Gynecol*. 2017 Feb 16. Pii: S0002-9378(17)30290-9. Doi: 10.1016/j.ajog.2017.02.021.
206. Lenis AT, Tan H-J, Halpern JA, Laviana AA, 38uch B, **Hu JC**. Ablative therapies for early stage kidney cancer and the evolving role of the urologist. *Urology Practice*. 2017 Mar; 4(2):162-168.
207. Veale JL, Capron AM, Nassiri N, Danovitch G, Gritsch HA, Waterman A, Del Pizzo J, **Hu JC**, Pycia M, McGuire S, Charlton M, Kapur S. Vouchers for Future Kidney Transplants to Overcome 'Chronological Incompatibility' Between Living Donors and Recipients. *Transplantation*. 2017 Mar 22. Doi: 10.1097/TP.0000000000001744.
208. Dinerman BF, Bernstein AN, Khani F, **Hu JC**. Intraductal Carcinoma of the Prostate: A Risk for Rapid Recurrence. *Urology*. 2017 Mar 28. Pii: S0090-4295(17)30293-5. Doi: 10.1016/j.urology.2017.03.030.
209. Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, **Hu JC**. Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-

- assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy. *European Urology*. 2017 Mar 30. 72(5):712-735.
210. Golan R, Bernstein AN, McClure TD, Sedrakyan A, Patel NA, Parekh DJ, Marks LS, **Hu JC**. Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review. *J Urol*. 2017 Apr 19. Pii: S0022-5347(17)54786-2. Doi: 10.1016/j.juro.2017.03.137.
 211. Golombos DM, Chughtai B, Trinh QD, Thomas D, Mao J, Te A, O'Malley P, Scherr DS, Del Pizzo J, **Hu JC**, Sedrakyan A. Minimally invasive vs open nephrectomy in the modern era: does approach matter? *World J Urol*. 2017 May 5. Doi: 10.1007/s00345-017-2040-6.
 212. Dinerman BF, Hauser NJ, **Hu JC**, Purohit RS. Robotic-assisted abdomino-perineal vesicourethral anastomotic reconstruction for 4.5 centimeter post-prostatectomy stricture. *Urol Case Rep*. 2017 May 31; 14:1-2. Doi: 10.1016/j.eucr.2017.05.005.
 213. Wallis CJD, Glaser A, **Hu JC**, Huland H, Lawrentschuk N, Moon D, Murphy DG, Nguyen PL, Resnick MJ, Nam RK. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. *Eur Urol*. 2017 Jun 10. Pii: S0302-2838(17)30495-5. Doi: 10.1016/j.eururo.2017.05.005.
 214. Tan HJ, Litwin MS, Chamie K, Saliba D, **Hu JC**. Trends in aging-related services during nephrectomy: implications for surgery in an aging population. *J Am Geriatr Soc*. 2017 Aug 11. Doi:10.1111/jgs.15046.
 215. Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, **Hu JC**, Scherr D, Schlegel P, Barbieri CE. Vasectomy and risk of prostate cancer in a screening trial. *Cancer Epidemiol Biomarkers Prev*. 2017 Aug 22. Pii:cebp.0776.2016. doi: 10.1158/1055-9965.
 216. Stone BV, Shoag J, Barbieri CE, **Hu JC**, Lee RK. Accurate Estimation of Prostate Size in the Evaluation of Nocturia. *Current Bladder Dysfunction Reports*. 2017;12(2):113-117.
 217. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, **Hu JC**, Sweeney CJ, Yu JB, Feng FY. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. *Annals of Oncology*. 2017;28(5):1098-1104.
 218. Dinerman BF, Khani F, Golan R, Bernstein AN, Cosiano MF, Margolis DJ, **Hu JC**. Population-based study of the incidence and survival for intraductal carcinoma of the prostate. *Urol Oncol*. 2017 Sep 14. Pii: S1078-1439(17)30425-8. Doi:10.1016/j.urolonc.2017.08.015.
 219. Tan HJ, Litwin MS, Chamie K, Saliba D, **Hu JC**. Trends in Aging-Related Services During Nephrectomy: Implications for Surgery in an Aging Population. *Journal of the American Geriatrics Society*. 2017;65(19):2290-2296.
 220. Shih YT, Shen C, **Hu JC**. Do robotic surgical systems improve profit margins? A cross-sectional analysis of California hospitals. *Value Health*. 2017 Sep;20(8):1221-1225. Doi:10.1016/j.jval.2017.05.010.
 221. Lipsitz SR, Fitzmaurice GM, Sinha D, Hevelone N, Giobannucci E, Trinh QD, **Hu JC**. Efficient computation of reduced regression models. *Am Stat*. 2017; 71(2):171-176. Doi: 10.1080/0031305.2017.1296375.
 222. Bernstein AN, Shoag JE, Golan R, Halpern JA, Schaeffer EM, Hsu WC, Nguyen PL, Sedrakyan A, Chen RC, Eggener SE, **Hu JC**. Contemporary incidence and outcomes of prostate cancer lymph node metastases. *J Urol*. 2017 Dec 26. Pii: S0022-5347(17)78181-5. Doi: 10.1016/j.juro.2017.12.048.

223. Golan R, Bernstein AN, McClure TD, Sedrakyan A, Patel NA, Parekh DJ, Marks LS, **Hu JC**. Partial gland treatment of prostate cancer using high-intensity focused ultrasound in the primary and salvage settings: a systematic review. *J Urol*. 2017.
224. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, **Hu JC**. Development of a nationally representative coordinated registry network for prostate ablation technologies. *J Urol*. 2018 Jan 4. Pii: S0022-5347(18)30007-7. Doi:10.1016/j.juro.2017.12.058.
225. Yang DD, Krasnova A, Nead KT, Choueiri TK, **Hu JC**, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. *Ann Oncol*. 2018 Feb 1;29(2):386-391. Doi: 10.1093/annonc/mdx744.
226. Faltas BM, Gennarelli RL, Elkin E, Ngyuen DP, **Hu JC**, Tagawa ST. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. *Urologic Oncology*. 2018;36(1).
227. Patel N, Halpern JA, Kasabwala K, Cricco-Lizza E, Herman M, Margolis D, Xu C, Robinson BD, Wang Y, McClure T, **Hu JC**. Multiple regions of interest on multi-parametric magnetic resonance imaging are not associated with increased detection of clinically significant prostate cancer on fusion biopsy. *J Urol*. 2018 Mar 5. Pii: S0022-5347(18)42470-6. Doi: 10.1016/j.juro.2018.03.002.
228. Laviana AA, Tan HJ, **Hu JC**, Weizer AZ, Chang SS, Barocas DA. Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing. *Curr Opin Urol*. 2018 Mar;28(2):108-114.
229. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, **Hu JC**, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF 3rd, Nguyen PL. Travel distance and stereotactic body radiotherapy for localized prostate cancer. *Cancer*. 2018 Mar 15; 124(6):1141-1149. Doi: 10.1002/cncr.31190.
230. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, **Hu JC**, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased vulnerability to poorer cancer-specific outcomes following recent divorce. *Am J Med*. 2018 Mar 16. Pii: S0002-9343(17)31233-9. Doi: 10.1016/j.amjmed.2017.11.039.
231. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Viridi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, **Hu JC**, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-targeted or standard biopsy for prostate-cancer diagnosis. *N Engl J Med*. 2018 Mar 18. Doi: 10.1056/NEJMoa1801993.
232. Golan R, Bernstein AN, Gu X, Dinerman BF, Sedrakyan A, **Hu JC**. Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life. *Cancer*. 2018 Mar 26. Doi: 10.1002/cncr.31287.
233. Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, **Hu JC**. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the

- Detection of Clinically Significant Prostate Cancer. *J Urol*. 2018 Apr;199(4):947-953. Doi: 10.1016/j.juro.2017.10.021.
234. Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, Wang Y, Margolis D, **Hu JC**. The role of systematic and targeted biopsies in light of overlap on magnetic resonance imaging ultrasound fusion biopsy. *European Urology Oncology*. 2018 Apr 27.
235. Accordino MK, Wright JD, Vasani S, Buono DL, **Hu JC**, Neugut AI, Hershman DL. Assessment of electronic alert to reduce overuse of granulocyte colony-stimulating factor in patients hospitalized for febrile neutropenia. *JAMA Oncol*. 2018 May 17. Doi:10.1001/jamaoncol.2018.0818.
236. Bach PV, Patel N, Najari BB, Oromendia C, Flannigan R, Brannigan R, Goldstein M, **Hu JC**, Kashanian JA. Changes in practice patterns in male infertility cases in the United States: the trend toward subspecialization. *Fertil Steril*. 2018 Jul 1;100(1):76-82. Doi:10.1016/j.fertnstert.2018.03.020.
237. Halpern JA, Dinerman B, Cosiano MF, Lee RK, Singer JS, **Hu JC**. National trends and characteristics of success in the urology match process. *Urology Practice*. 2018 Jul;5:311-316.
238. Taylor BL, Xia L, Guzzo TJ, Scherr DS, **Hu JC**. Frailty and greater health care resource utilization following major urologic oncology surgery. *European Urology Oncology*. 2018 Jul 6.
239. Ahlering T, Huynh LM, Kaler KS, Williams S, Osann K, Joseph J, Lee D, Davis JW, Abaza R, Kaouk J, Patel V, Kim IY, Porter J, **Hu JC**. Unintended consequences of decreased PSA-based prostate cancer screenings. *World J Urol*. 2018 Jul 12. Doi: 10.1007/s00345-018-2407-3.
240. Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, Sun M, Nabi J, Nguyen PL, **Hu JC**, Kibel AS, Choueiri TK, Kluth LA, Trinh QD. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. *Prostate Cancer Prostatic Dis*. 2018 Aug 31. Doi: 10.1038/s41391-018-0083-4.
241. Kasabwala K, Patel N, Cricco-Lizza E, Shimpi AA, Weng S, Montanagh S, Khani F, Wu Y, Margolis DJ, Banerjee S, Robinson BD, **Hu JC**. The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy. *European Urology Oncology*. 2018 Aug. doi:10.1016/j.euo.2018.07.005
242. Kim SJ, Vickers AJ, **Hu JC**. Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening. *JAMA Oncol*. 2018 Sep. doi:10.1001/jamaoncol.2018.4160
243. Belarmino A, Walsh R, Alshak M, Patel N, Wu R, **Hu JC**. Feasibility of a mobile health application to monitor recovery and patient reported outcomes after robotic-assisted radical prostatectomy. *European Urology Oncology*. 2018 Sep. doi: 10.1016/j.euo.2018.08.016
244. Sussman R, Carvalho FL, Harbin A, Zheng C, Lynch JH, Stamatakis L, Hwang J, Williams SB, **Hu JC**, Kowalczyk KJ. Survival and secondary interventions following treatment for locally-advanced prostate cancer. *Can J Urol*. 2018 Oct;25(5):9516-9524.
245. Vis AN, van der Poel HG, Ruiters AEB, **Hu JC**, Tewari AK, Rocco B, Patel VR, Razdan S, Nieuwenhuijzen JA. Posterior Anterior, and the Periurethral Surgical Reconstruction of Urinary Continence Mechanisms in Robot-assisted Radical Prostatectomy: A Description and Video Compilation of Commonly Performed Surgical Techniques. *European Urology*. 2018 Dec 1. Doi:10.1016/j.eururo.2018.11.035

246. Weiner AB, Ko OS, Zhu A, Spratt DE, **Hu JC**, Schaeffer EM. National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. *Urol Onco*. 2019 Jan 2. Doi: 10.1016/j.urolonc.2018.12.022.
247. Gross MD, Al Hussein Al Awamlh B, **Hu JC**. Will long term oncologic follow-up make the case for robotic assisted radical cystectomy? *Transl Androl Urol*. 2018 Dec;7(Suppl 6):S696-S698. Doi: 10.21037/tau.2018.11.01.
248. Shoag JE, Patel N, Posada L, Halpern JA, Stark T, **Hu JC**, Eisner BH. Kidney stones and risk of narcotic use. *J Urol*. 2019 Feb 25:101097JU00000000000000197. Doi: 10.1097/JU.00000000000000197.
249. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, **Hu JC**. SPARED Collaboration: Patient selection for partial gland ablation in men with localized prostate cancer. *J Urol*. 2019 May 30:101097JU00000000000000357. Doi: 10.1097/JU.00000000000000357.
250. Margolis DJA, **Hu JC**. Vying for Standardization of Bladder Cancer MRI Interpretation and Reporting: VI-RADS. *Radiology*. 2019 Jun;291(3):675-676. Doi: 10.1148/radiol.2019190648
251. Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, **Hu JC**, Kaul S, Kamat AM, Gore JL, Mehta HB. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. *JAMA Surg*. 2019 Jun 5:e191629. Doi: 10.1001/jamasurg.2019.1629.
252. Gross MD, Alshak MN, Shoag JE, Laviana AA, Gorin MA, Sedrakyan A, **Hu JC**. Healthcare Costs of Post-Prostate Biopsy Sepsis. *Urology*. 2019 Jun 21. Pii: S0090-4295(19)30550-3. Doi: 10.1016/j.urology.2019.06.011.
253. Alshak MN, Gross MD, Shoag JE, Laviana AA, Gorin MA, Sedrakyan A, **Hu JC**. Data on the quality and methods of studies reporting healthcare costs of post-prostate biopsy sepsis. *Data Brief*. 2019 Jul 25;25:104307. Doi: 10.1016/j.dib.2019.104307.
254. Gross MD, Al Hussein Al Awamlh B, Shoag JE, Mauer E, Banerjee S, Margolis DJ, Mosquera JM, Hamilton AS, Schymura MJ, **Hu JC**. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. *BMJ Surgery, Interventions, & Health Technologies*. 2019 Aug;1:e000010. Doi: 10.1136/bmjst-2019-000010.
255. Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, **Hu JC**, Kaul S, Kamat AM, Gore JL, Mehta HB. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients with Localized Muscle-Invasive Bladder Cancer. *JAMA Surg*. 2019 Aug 1;154(8):e191629. Doi: 10.1001/jamasurg.2019.1629.
256. Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, Baltich R, Margolis DJ, **Hu JC**. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2019 Sep 4. Pii: S2588-9311(19)30121-X. doi: 10.1016/j.euo.2019.08.001.
257. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Freidlin B, **Hu JC**, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver J. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop. *J Urol*. 2019 Sep 10:101097JU00000000000000532. Doi: 10.1097/JU.00000000000000532.

258. Gross MD, Marks LS, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, **Hu JC**. Variation in MRI-Ultrasound Fusion Targeted Biopsy Outcomes in Asian-American Men: A Multi-Center Study. *J Urol*. 2019 Sep 10:101097JU00000000000000534. Doi: 10.1097/JU.0000000000000534.
259. Patel NA, Sedrakyan A, Bianco F, Etzioni R, Gorin MA, Hsu WC, Mao J, Nguyen PL, Schaeffer E, Shoag J, Vickers A, **Hu JC**. Definitive and sustained increase in prostate cancer metastases in the United States. *Urol Oncol*. 2019 Sep 12. Pii: S1078-1439(19)30320-5. Doi: 10.1016/j.urolonc.2019.08.002.
260. Alshak MN, Patel N, Gross MD, Margolis DJ, **Hu JC**. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy. *Urology*. 2019 Sep 27. Pii: S0090-4295(19)30842-8. Doi: 10.1016/j.urology.2019.07.049.
261. Gross MD, Al Hussein Al Awamlh B, **Hu JC**. Assessing Treatment-Related Toxicity Using Administrative Data, Patient-Reported Outcomes, or Physician-Graded Toxicity: Where Is the Truth? *Semin Radiat Oncol*. 2019 Oct;29(4):333-337. Doi: 10.1016/j.semradonc.2019.05.007.
262. Goh AC, Belarmino A, Patel NA, Sun T, Sedrakyan A, Bochner BH, **Hu JC**. A population-based study of ureteroenteric strictures after open and robot-assisted radical cystectomy. *Urology*. 2019 Oct 13. Pii: S0090-4295(19)30871-4. Doi: 10.1016/j.urology.2019.07.054.
263. Tzeng M, Cricco-Lizza E, Al Hussein Al Awamlh B, Pantuck M, Margolis DJ, Yu M, **Hu JC**. IDEAL Stage 2a experience with in-office, transperineal MRI/ultrasound software fusion targeted prostate biopsy. *BMJ Surgery, Interventions & Health Technologies*. 2019 Nov;1:e000025. Doi: 10.1136/bmjst-2019-000025.
264. Al Hussein Al Awamlh B, Ma X, Christos P, **Hu JC**, Shoag JE. Active Surveillance for Black Men with Low-Risk Prostate Cancer in the United States. *N Engl J Med*. 2019 Dec 26;381(26):2581-2582. Doi: 10.1056/NEJMc1912868.
265. Mahal AR, Chavez J, Yang DD, Kim DW, Cole AP, **Hu JC**, Trinh QD, Yu JB, Nguyen PL, Mahal BA. Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. *Am J Clin Oncol*. 2019 Dec 31. Doi: 10.1097/COC.0000000000000588.
266. Nabi J, Friedlander DF, Chen X, Cole AP, **Hu JC**, Kibel AS, Dasgupta P, Trinh QD. Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. *JAMA Netw Open*. 2020 Jan 3;3(1):e1919185. Doi: 10.1001/jamanetworkopen.2019.19185.
267. Al Hussein Al Awamlh B, Margolis DJ, Gross MD, Natarajan S, Priester A, Hectors S, Ma X, Mosquera JM, Liao J, **Hu JC**. Prostate Multiparametric Magnetic Resonance Imaging Features Following Partial Gland Cryoablation. *Urology*. 2020 Jan 15. Pii: S0090-4295(20)30022-4. Doi: 10.1016/j.urology.2020.01.005.
268. Mahase SS, D'Angelo D, Kang J, **Hu JC**, Barbieri CE, Nagar H. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. *JAMA Netw Open*. 2020 Feb 5;3(2):e1920471. Doi: 10.1001/jamanetworkopen.2019.20471.
269. Al Hussein Al Awamlh B, Ma X, Scherr D, **Hu JC**, Shoag JE. Temporal Changes in Demographic and Clinical Characteristics of Men With Prostate Cancer Electing for Conservative Management in the United States. *Urology*. 2020 Mar;137:60-65. Doi: 10.1016/j.urology.2019.12.007.
270. Al Hussein Al Awamlh B, Marks LS, Sonn GA, Natarajan S, Fan RE, Gross MD, Mauer E, Banerjee S, Hectors S, Carlsson S, Margolis DJ, **Hu JC**. Multicenter analysis of clinical and

- MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. *Urol Oncol*. 2020 Apr. pii:S1078-1439(20)30125-3. Doi:10.1016/j.urolonc.2020.03.019.
271. Shoag JE, Cai PY, Gross MD, Gaffney C, Li D, Mao J, Nowels M, Scherr DS, Sedrakyan A, **Hu JC**. Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance. *Cancer*. 2020 Apr. doi:10.1002/cncr.32821.
 272. Shoag JE, Gaffney C, Pantuck M, Sun T, Gorin M, Schaeffer EM, Sedrakyan A, Vickers A, **Hu JC**. Risk factors for infection after prostate biopsy in the United States. *Urology*. 2020 Apr. doi:10.1016/j.urology.2019.12.023.
 273. Weiner AB, Vo AX, Desai AS, **Hu JC**, Spratt DE, Schaeffer EM. Changes in prostate-specific antigen at time of prostate cancer diagnosis following Medicaid expansion in young men. *Cancer*. 2020 Apr. doi: 10.1002/cncr.32930.
 274. Egan J, Marhamati S, Carvalho FLF, Davis M, O'Neill J, Lee H, Lynch JH, Hankins RA, **Hu JC**, Kowalczyk KJ. Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-step Guide. *Eur Urol*. 2020 Jun 11:S0302-2838(20)30350-X. doi: 10.1016/j.eururo.2020.05.010.
 275. Shoag JE, Nyame Y, Gulati R, Etzioni R, **Hu JC**. Reconsidering the Tradeoffs of Prostate Cancer Screening. *N Engl J Med*. 2020 Jun 18;382(25):2465-2468. Doi: 10.1056/NEJMSb2000250.
 276. Agrawal V, Ma X, **Hu JC**, Barbieri CE, Nagar H. Active Surveillance for Men with Intermediate Risk Prostate Cancer. *J Urol*. 2020 Jul 13:101097JU0000000000001241. Doi: 10.1097/JU.0000000000001241.
 277. Al Hussein Al Awamlh B, Ballman KV, Ma X, **Hu JC**, Shoag JE. Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States. *Prostate Cancer Prostatic Dis*. 2020 Jul 13. Doi: 10.1038/s41391-020-0252-0.
 278. Agrawal V, Ma X, **Hu JC**, Barbieri CE, Nagar H. Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. *JAMA Netw Open*. 2020 Aug 3;3(8):e2014674. Doi: 10.1001/jamanetworkopen.2020.14674.
 279. Ramaswamy A, Yu M, Drangsholt S, Ng E, Culligan PJ, Schlegel PN, **Hu JC**. Patient Satisfaction With Telemedicine During the COVID-19 Pandemic: Retrospective Cohort Study. *J Med Internet Res*. 2020 Sep 9;22(9):e20786. Doi: 10.2196/20786.
 280. **Hu, JC**, Basourakos SP, Futterer J. Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation. *European Urology*. 2020 Nov 18. Doi: 10.1016/j.eururo.2020.10.036.
 281. Kowalczyk KJ, Davis M, O'Neill J, Lee H, Orzel J, Rubin RS, **Hu JC**. Impact of Retzius-sparing Versus Standard Robotic-assisted Radical Prostatectomy on Penile Shortening, Peyronie's Disease, and Inguinal Hernia Sequelae. *European Urology Open Science*. 2020 Dec; 22:17-22.
 282. **Hu JC**, Edhaie B, Sandhu J, Sjoberg DD, Carlsson SV, Tzeng M, Vickers AJ. Asian-American Race and Urinary Continence After Radical Prostatectomy. *European Urology Open Science*. 2020 Dec;22:51-53. Doi: 10.1016/j.euro.2020.10.004.
 283. Ramaswamy A, Pichs A, Klarich JV, Basourakos SP, Lee RK, Lamb DJ, Schaeffer EM, **Hu JC**. Influence of Department Leadership on Scholarly Productivity and Research Funding in

- Academic Urology. *Urology*. 2021 Jan 19;S0090-4295(21)00066-2. Doi: 10.1016/j.urology.2021.01.011.
284. Arenas-Gallo C, Shoag JE, **Hu JC**. Optimizing Surgical Techniques in Robot-Assisted Radical Prostatectomy. *Urol Clin North Am*. 2021 Feb;48(1):1-9. Doi:10.1016/j.ucl.2020.09.002.
285. Chang TC, Seufert C, Eminaga O, Shkolyar E, **Hu JC**, Liao JC. Current Trends in Artificial Intelligence Application for Endourology and Robotic Surgery. *Urol Clin North Am*. 2021 Feb;48(1):151-160. Doi: 10.1016/j.ucl.2020.09.004.
286. **Hu JC**, Shoag JE. Two Decades of Robotics in Urology: Origins, Current Practice, and Directions. *Urol Clin North Am*. 2021 Feb;48(1):xv. Doi: 10.1016/j.ucl.2020.10.002.
287. Lange J, Remmers S, Gulati R, Bill-Axelsson A, Johansson JE, Kwiatkowski M, Auvinen A, Hugosson J, **Hu JC**, Roobol MJ, Carlsson SV, Etzioni R. Impact of cancer screening on metastasis: A prostate cancer case study. *J Med Screen*. 2021 Feb 9;969141321989738. Doi: 10.1177/0969141321989738.
288. Lewicki P, Basourakos SP, Al Awamlh BAH, Wu X, **Hu JC**, Schlegel PN, Shoag JE. Estimating the Impact of COVID-19 on Urology: Data from a Large Nationwide Cohort. *Eur Urol Open Sci*. 2021 Mar;25:52-56. Doi: 10.1016/j.euros.2021.01.006.
289. Basourakos SP, Allaway MJ, Ross AE, Schaeffer EM, **Hu JC**, Gorin MA. Local anaesthetic techniques for performing transperineal prostate biopsy. *Nat Rev Urol*. 2021 Mar 1. Doi: 10.1038/s41585-021-00443-7.
290. Lewicki PJ, Basourakos SP, Qiu Y, **Hu JC**, Sheyn D, Hijaz A, Shoag JE. Effect of a Randomized, Controlled Trial on Surgery for Cervical Cancer. *N Engl J Med*. 2021 Apr 29;384(17):1669-1671. Doi: 10.1056/NEJMc2035819.
291. Basourakos SP, Ramaswamy A, Yu M, Margolis DJ, **Hu JC**. Racial Variation in Membranous Urethral Length and Postprostatectomy Urinary Function. *Eur Urol Open Sci*. 2021 May;27:61-64. Doi: 10.1016/j.euros.2021.03.001.
292. Hectors SJ, Chen C, Chen J, Wang J, Gordon S, Yu M, Al Hussein Al Awamlh B, Sabuncu MR, Margolis DJA, **Hu JC**. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions. *J Magn Reson Imaging*. 2021 May 10. Doi: 10.1002/jmri.27692.
293. Hur SS, Tzeng M, Cricco-Lizza E, Yu M, Ancker J, Abramson E, Saigal C, Ross A, **Hu JC**. Perceptions of partial gland ablation for prostate cancer among men on active surveillance: A qualitative study. *BMJ Surgery, Interventions & Health Technologies*. 2021. Doi: 10.1101/2020.09.15.20195388.
294. Basourakos SP, Kowalczyk KJ, Moschovas M, Dudley V, Shoag JE, Patel V, **Hu JC**. Robot-Assisted Radical Prostatectomy Maneuvers to Attenuate Erectile Dysfunction: Technical Description and Video Compilation. *J Endourol*. 2021 May 20. Doi: 10.1089/end.2021.0081.
295. Lewicki P, Arenas-Gallo C, Basourakos SP, Punjani N, Venkat S, Scherr DS, **Hu JC**, Shoag JE. Changes in Urologic Operative Practice at the Beginning of the COVID-19 Pandemic in a Large, National Cohort. *Front Oncol*. 2021 May 7;11:684787. Doi: 10.3389/fonc.2021.684787. eCollection 2021.
296. Al Hussein Al Awamlh B, Patel N, Ma X, Calaway A, Ponsky L, **Hu JC**, Shoag JE. Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions. *Front Oncol*. 2021 May 19;11:644885. Doi: 10.3389/fonc.2021.644885. eCollection 2021.
297. Basourakos SP, Tzeng M, Lewicki PJ, Patel K, Awamlh BAH, Venkat S, Shoag JE, Gorin MA, Barbieri CE, **Hu JC**. Tissue-Based Biomarkers for the Risk Stratification of Men With

- Clinically Localized Prostate Cancer. *Front Oncol*. 2021 May 28;11:676716. Doi: 10.3389/fonc.2021.676716. PMID: 34123846; PMCID: PMC8193839.
298. Gaffney CD, Cai P, Li D, Margolis D, Sedrakyan A, **Hu JC**, Shoag J. Increasing Utilization of MRI Before Prostate Biopsy in Black and Non-Black Men: An Analysis of the SEER-Medicare Cohort. *AJR Am J Roentgenol*. 2021 Jun 23:1-6. Doi: 10.2214/AJR.20.23462.
 299. Kowalczyk KJ, Madi RH, Eden CG, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi AM, Hwang J, Kim IY, **Hu JC**. Comparative Outcomes of Salvage Retzius-Sparing Versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. *J Urol*. 2021 Jun 28:101097JU0000000000001939. Doi: 10.1097/JU.0000000000001939.
 300. Cricco-Lizza E, Berg RNWV, Laviana A, Pantuck M, Basourakos S, Salami SS, Hung AJ, Margolis DJ, **Hu JC**, McClure TD. Comparative Effectiveness and Tolerability of Transperineal MRI-targeted Prostate Biopsy under Local versus Sedation. *Urology*. 2021 Jul 1:S0090-4295(21)00592-6. Doi: 10.1016/j.urology.2021.06.023.
 301. Basourakos SP, Lewicki PJ, Ramaswamy A, Cheng E, Dudley V, Yu M, Karir B, Hung AJ, Khani F, **Hu, JC**. Clipless Robotic-assisted Radical Prostatectomy and Impact on Outcomes. *Eur Urol Focus*. 2021 Jul 8. Doi: 10.1016/j.euf.2021.06.010.
 302. Tzeng M, Vertosick E, Basourakos SP, Eastham JA, Ehdaie B, Scardino PT, Vickers AJ, **Hu JC**. Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms. *Eur Urol Focus*. 2021 Jun 15;30:13-15. doi: 10.1016/j.euros.2021.06.002.
 303. Chang P, Wagner AA, Regan MM, Smith JA, Saigal CS, Litwin MS, **Hu JC**, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Partin AW, Wood DP, Crociani CM, Greenfield TK, Patil D, Hembroff LA, Davis K, Stork L, Spratt DE, Wei JT, Sanda MG. Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. *J Urol*. 2021 Aug 26;101097JU0000000000002176. doi: 10.1097/JU.0000000000002176.
 304. Clements MB, Gmelich CC, Vertosick EA, **Hu JC**, Sandhu JS, Scardino PT, Eastham JA, Laudone VP, Touijer KA, Coleman JA, Vickers AJ, Ehdaie B. Have urinary function outcomes after radical prostatectomy improved over the past decade? [published online ahead of print, 2021 Nov 1]. *Cancer*. 2021;10.1002/cncr.33994. doi:10.1002/cncr.33994
 305. Kinnaird A, Brisbane W, Kwan L, Priestler A, Chuang R, Barsa DE, Delfin M, Sisk A, Margolis D, Felker E, **Hu JC**, Marks L. A prostate cancer risk calculator (PCRC-MRI): Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men [published online ahead of print, 2021 Oct 18]. *Can Urol Assoc J*. 2021;10.5489/cuaj.7380. doi:10.5489/cuaj.7380
 306. Chen C, Yang Z, Sweeney E, Hectors SJ, **Hu JC**, Margolis DJ. Prostate heterogeneity correlates with clinical features on multiparametric MRI. *Abdom Radiol (NY)*. 2021;46(11):5369-5376. doi:10.1007/s00261-021-03221-6
 307. Cricco-Lizza E, Wilcox Vanden Berg RN, Laviana A, Pantuck M, Basourakos SP, Salami SS, Hung AJ, Margolis DJ, **Hu JC**, McClure TD. Comparative Effectiveness and Tolerability of Transperineal MRI-Targeted Prostate Biopsy under Local versus Sedation. *Urology*. 2021;155:33-38. doi:10.1016/j.urology.2021.06.023
 308. Basourakos SP, Alshak MN, Lewicki PJ, Cheng E, Tzeng M, DeRosa AP, Allaway MJ, Ross AE, Schaeffer EM, Patel HD, **Hu JC**, Gorin MA. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. *Eur Urol Open Sci*. 2022;37:53-63. Published 2022 Jan 29. doi:10.1016/j.euros.2022.01.001

309. Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER, Sisk AE, **Hu JC**, Marks LS. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling [published online ahead of print, 2022 Jan 31]. *Eur Urol.* 2022;S0302-2838(22)00010-0. doi:10.1016/j.eururo.2022.01.008
310. Abedian S, Sholle ET, Adekkanattu PM, Cusick MM, Weiner SE, Shoag JE, **Hu JC**, et al. Automated Extraction of Tumor Staging and Diagnosis Information From Surgical Pathology Reports. *JCO Clin Cancer Inform.* 2021;5:1054-1061. doi:10.1200/CCI.21.00065
311. Cheng E, Davuluri M, Lewicki PJ, **Hu JC**, Basourakos SP. Developments in optimizing transperineal prostate biopsy. *Curr Opin Urol.* 2022 Jan 1;32(1):85-90. doi: 10.1097/MOU.0000000000000947. PMID: 34783715; PMCID: PMC8622440.
312. Borregales LD, DeMeo G, Gu X, Cheng E, Dudley V, Schaeffer EM, Nagar H, Carlsson S, Vickers A, **Hu JC**. Grade Migration of Prostate Cancer in the United States during the last decade [published online ahead of print, 2022 Mar 28]. *J Natl Cancer Inst.* 2022;djac066. doi:10.1093/jnci/djac066
313. Zhu A, **Hu JC**. Beyond the *AJR*: Racial Disparities in Prostate MRI Utilization [published online ahead of print, 2022 May 4]. *AJR Am J Roentgenol.* 2022;10.2214/AJR.22.27889. doi:10.2214/AJR.22.27889
314. Basourakos SP, Al Hussein Al Awamlh B, Borregales LD, Abrahami P, Sedrakyan A, Shoag JE, **Hu JC**. A comparative population-based analysis of peritoneal carcinomatosis in patients undergoing robotic-assisted and open radical cystectomy [published online ahead of print, 2022 Apr 27]. *Int Urol Nephrol.* 2022;10.1007/s11255-022-03216-2. doi:10.1007/s11255-022-03216-2
315. Basourakos, S., Gulati, R., Vince, R., Spratt, D., Lewicki, P., Hill, A., Nyame, Y., Cullen, J., Markt, S., Barbieri, C., Hu, J., Trapl, E. and Shoag, J. Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men [published online ahead of print, 2022 May 15]. *NEJM Evidence.* 2022. DOI:<https://doi.org/10.1056/EVIDoa2200031>

Reviews

1. Freire MP, Choi WW, Lei Y, Weinberg AC, Carvas F, **Hu JC**. Overcoming the learning curve for robotic assisted laparoscopic radical prostatectomy. *Urol Clin of North AM.* 2010;37(1):37-47.
2. Yu HY, Ulmer W, Kowalczyk KJ, **Hu JC**. Health services research in urology. *World J Urol.* 2011 Jun;29(3):273-6.
3. Kowalczyk KJ, Yu HY, Ulmer W, Williams SB, **Hu JC**. Outcomes assessment in men undergoing open retropubic radical prostatectomy, laparoscopic radical prostatectomy, and robotic-assisted radical prostatectomy. *World J Urol.* 2012 Feb;30(1):85-9.
4. Chade DC, Eastham J, Graefen M, **Hu JC**, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. *Eur Urol.* 2012 May;61(5):961-71.
5. **Hu JC**, Lin DW. Current status of focal primary therapy for prostate cancer. *Urol Oncol.* 2012 Nov;30(6):942-3
6. Yu HY, Friedlander DF, Patel S, **Hu JC**. The current status of robotic oncologic surgery. *CA*

- Cancer J Clin. 2013 Jan;63(1):45-56.
7. Carter S, Le JD, **Hu JC**. Anatomic and technical considerations for optimizing recovery of sexual function during robotic-assisted radical prostatectomy. *Curr Opin Urol*. 2013 Jan;23(1):88-94
 8. Huang KH, Carter SC, Shih YC, **Hu JC**. Robotic and standard open radical prostatectomy: oncological and quality-of-life outcomes. *J Comp Eff Res*. 2013 May;2(3):293-9.
 9. Williams SB, **Hu JC**. Salvage robotic assisted laparoscopic radical prostatectomy: indications and outcomes. *World J Urol*. 2013 Jun;31(3):431-4.
 10. Huang KH, Carter SC, **Hu JC**. Does robotic prostatectomy meet its promise in the management of prostate cancer. *Curr Urol Rep*. 2013 Jun;14(3):184-91.
 11. Laviana AA, **Hu JC**. A comparison of the robotic-assisted versus retropubic radical prostatectomy. *Minerva Urol Nefrol*. 2013 Sep;65(3):161-70
 12. Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, **Hu JC**, Shariat SF, Sun M, Vickers AJ. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol*. 2013 Nov;64(5):786-98. doi: 10.1016/j.eururo.2013.08.013.
 13. Bolenz C, Freedland SJ, Hollenbeck BK, Lotan Y, Lowrance WT, Nelson JB, **Hu JC**. Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. *Eur Urol*. 2014 Feb;65(2):316-24.
 14. Laviana AA, **Hu JC**. Current controversies and challenges in robotic-assisted, laparoscopic, and open partial nephrectomies. *World J Urol*. 2014 Jun;32(3):591-6.
 15. Williams SB, Prado K, **Hu JC**. Economics of Robotic Surgery: Does It Make Sense and for Whom? *Urol Clin North Am*. 2014 Nov;41(4):591-596.
 16. Kaplan AL, **Hu JC**, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F. Testosterone Therapy in Men With Prostate Cancer. *Eur Urol*. 2015 Dec 21. pii: S0302-2838(15)01213-0. doi: 10.1016/j.eururo.2015.12.005.
 17. Halpern JA, Sedrakyan A, Hsu WC, **Hu JC**. Reply to Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf? *Cancer*. 2016 Dec 20. doi: 10.1002/cncr.30433.
 18. McClure TD, Margolis DJ, **Hu JC**. Partial gland ablation in the management of prostate cancer: a review. *Curr Opin Urol*. 2017 Mar. doi: 10.1097/MOU.0000000000000376.
 19. Kasabwala K, Patel NA, **Hu JC**. Review of optimal techniques for robotic-assisted radical prostatectomy. *Curr Opin Urol*. 2018 Mar;28(2):102-107.
 20. Gross MD, Shoag JE, **Hu JC**. Is in-office transperineal biopsy the future of prostate cancer diagnosis? *Curr Opin Urol*. 2019 Jan;29(1):25-26. doi: 10.1097/MOU.0000000000000567.
 21. Carlsson SV, Vickers AJ, Gonsky JP, Hay JL, **Hu JC**. Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review. *Eur Urol*. 2021 Mar;79(3):330-333. doi: 10.1016/j.eururo.2020.11.011.
 22. Tzeng M, Basourakos SP, Lewicki PJ, **Hu JC**, Lee RK. New Endoscopic In-office Surgical Therapies for Benign Prostate Hyperplasia: A Systematic Review. *Eur Urol Focus*. 2021 Mar 1:S2405-4569(21)00056-0. doi: 10.1016/j.euf.2021.02.013.
 23. **Hu JC**, McClure TD, Margolis DJ. Editorial Comment. *J Urol*. 2022;207(1):92-93. doi:10.1097/JU.0000000000002168.01

Chapters

1. DeWolf WC and **Hu JC**. Radical Nephrectomy for Renal Cell Carcinoma. In: *Mastery of Surgery*

5th Edition. Fischer JE, and Brand KI, editors. Philadelphia: Lippincott, Williams and Wilkins; 2007. p. 1688-1702.

2. Laviana AA, Carter SC, **Hu JC**. The transperitoneal robotic assisted radical prostatectomy. In: Radical Prostatectomy. Eastham JA and Schaeffer EM. Springer.
4. Oh, WK, **Hu JC**. Advances and Controversies in Prostate Cancer, An Issue of Urologic Clinics-E-Book. Elsevier Health Sciences. 2010.
3. Treat E and **Hu JC**. Transplant Nephrectomy. In: Glenn's Urologic Surgery, 8th Edition. Graham SD and Keane TE, editors. Philadelphia: Lippincott, Williams and Wilkins; Mar 2016.
4. Laviana AA and **Hu JC**. Understanding the market forces and opportunity costs of robotic surgery. In: Perioperative Management in Robotic Surgery. Kaye A and Urman R, editors. Cambridge. Aug 2017.